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A B S T R A C T
Background
Osteoporosis is a bone mineralisation disorder occurring in about one third of adults with cystic fibrosis (CF). Bisphosphonates can
increase bone mineral density (BMD) and decrease the risk of new fractures in post-menopausal women and people receiving long-
term oral corticosteroids.
Objectives
To assess the effects of bisphosphonates on the frequency of fractures, BMD, quality of life, adverse events, trial withdrawals, and
survival in people with CF.
Search methods
We searched the CF and Genetic Disorders Group Trials Register of references (identified from electronic database searches and
handsearches of journals and abstract books) on 29 October 2008.
Additional searches of Pubmed were performed on 01 November 2008.
Selection criteria
Randomised controlled trials of at least six months duration studying bisphosphonates in people with CF.
Data collection and analysis
Two authors independently selected trials and extracted data. Trial investigators were contacted to obtain missing data.
Main results
Seven trials were identified and five (with a total of 145 adult participants) were included.
Data were combined when available from four included studies in participants without a lung transplant. This showed that there was
no significant reduction in fractures between groups. However, after six months, the percentage change in BMD increased in those
on bisphosphonates at the lumbar spine, mean difference (MD) 4.61 (95% confidence interval (CI) 3.90 to 5.32) and at the hip,
MD 3.35 (95% CI 1.63 to 5.07); but did not significantly change at the distal forearm, MD -0.49 (95% CI -2.42-1.45). There was
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clinical heterogeneity between studies and not all studies reported all outcomes. Bone pain was the most common adverse event with
intravenous agents. Flu-like symptoms were also increased in those taking bisphosphonates.
In participants with a lung transplant (one study), intravenous pamidronate did not change the number of new fractures. At axial sites,
BMD increased with treatment compared to controls: percentage change in bone mineral density at lumbar spine, MD 6.20 (95% CI
4.28 to 8.12) and femur MD 7.90 (95% CI 5.78 to 10.02).
Authors’ conclusions
Oral and intravenous bisphosphonates increase BMD in people with CF. Severe bone pain and flu-like symptoms may occur with
intravenous agents. Additional trials are needed to determine if bone pain is more common or severe (or both) with the more potent
zoledronate and if corticosteroids ameliorate or prevent these adverse events. Trials in larger populations are needed to determine effects
on fracture rate and survival.
P L A I N L A N G U A G E S U M M A R Y
Bisphosphonates for osteoporosis in people with cystic fibrosis
Cystic fibrosis (CF) is a serious genetic disorder that has effects on many organs (e.g. lung, pancreas). It commonly results in reduced
bone mineral density (BMD), known as osteoporosis, which increases the susceptibility to fractures. The acute and chronic effects of
fractures (e.g. rib and vertebral) may contribute to worsening of lung disease. Bisphosphonates are drugs that increase bone mineral
density (BMD) by inhibiting bone resorption. They are used to treat osteoporosis caused by menopause or the use of corticosteroid
drugs.
The evidence available was limited to four trials assessing participants without lung transplants (total of 111 adult participants) and one
trial with 34 adult participants who had undergone lung transplantation. Bisphosphonates consistently increased BMD at the lumbar
spine and hip regions. The rates of fractures (vertebral and non-vertebral) or deaths were not reduced by bisphosphonate therapy.
However, this may be related to the small numbers of participants involved and the short duration of the trials. Severe bone pain and
flu-like symptoms were commonly associated with intravenous bisphosphonates, especially in people not using corticosteroids. More
research is needed to assess the effect of pre-treatment with corticosteroids. Additional trials are needed to determine if bone pain is
more common or severe (or both) with the more potent zoledronate and if corticosteroids ameliorate or prevent these adverse events.
Trials in larger populations are needed to determine effects on fracture rate and survival.
B A C K G R O U N D
Description of the condition
Cystic fibrosis (CF) is the most common serious autosomal reces-
sive genetic disorder in the Caucasian population. It is caused by
mutations in the cystic fibrosis transmembrane regulator (CFTR)
gene (Riordan 1989). This genetic disorder occurs in approxi-
mately one in 3500 live births in the United States; the incidence
varies between racial and ethnic groups, being more common in
Caucasians (Cystic Fibrosis Foundation Patient Registry 2006).
One in 25 individuals carry the defective gene (Yankaskas 1999).
The major components of CF are lung disease and pancreatic in-
sufficiency. In the past, only one third of individuals with CF lived
to the age of 18 (Yankaskas 1999). However, recent advances in
medical science and technology have increased the life expectancy
of people with CF into the third and fourth decades of life. Hence,
as survival improves, long-term sequelae of the disease, such as
osteoporosis (Boyle 2006), liver disease (Colombo 2007), and di-
abetes mellitus (Costa 2005) are of increasing significance.
Osteoporosis is a disorder of bone mineralisation that decreases
bone mineral density (BMD) and makes bones brittle and more
susceptible to fracture. Osteopenia refers to a milder degree of
bone demineralisation. Bone density is currently measured using
dual-energy X-ray absorptiometry (DXA), which measures abso-
lute bone density in grams per centimetre squared (gm/cm2) and
can be compared to a population mean. It is usual to express BMD
as standard deviations from the population mean, either as a Z-
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score (compared to age- and sex-matched data) or a T-score (com-
pared to the healthy young adult mean for the participant’s sex).
The World Health Organization (WHO) classifies osteopenia as
a T-score of between -1 and -2.5, and osteoporosis as a T-score
of -2.5 or less (Kanis 1994). The International Society for Clini-
cal Densitometry has recently updated recommendations with re-
gard to BMD reporting (ISCDOfficial Positions 2007). However,
BMD is only one of the factors that determine the risk of fracture.
It is osteoporotic fractures which account for the morbidity and
mortality associated with osteoporosis (Cummings 1995).
Decreased BMD has been observed in children (Bianchi 2006;
Sermet-Gaudelus 2007), adolescents (Bianchi 2006; Buntain
2004; Caldeira 2008) and adults ( Bianchi 2006; Buntain 2004)
with CF. A longitudinal study of 151 adults with CF aged 15 to
52 years showed that 34% of participants had a DXA Z-score of
≤ -2 (Haworth 2001). Other studies have not detected differences
in BMD between children with CF and those without (Buntain
2004), but inadequate bone mass accrual during childhood and
adolescence has been reported (Buntain 2006). Definitions of os-
teoporosis and osteopenia may vary between studies.
The aetiology of CF-related bone disease is thought to bemultifac-
torial. The pathophysiology of the observed imbalance of increased
bone resorption and decreased bone formation has not been clearly
delineated (Boyle 2006). Abnormalities of calciummetabolism in-
dependent of vitamin D status have been reported (Greer 2003).
Proposed contributing factors include exocrine pancreatic insuf-
ficiency; vitamin D, vitamin K or calcium deficiency; poor nutri-
tion and growth resulting in low body weight; systemic inflam-
matory cytokines; use of exogenous glucocorticoids; sex hormone
insufficiency, diabetes mellitus; and physical inactivity resulting in
decreased weight bearing activity (Aris 2005; Boyle 2006). Many
of these factors are inter-related (e.g. pancreatic exocrine insuffi-
ciency contributing to malabsorption of vitamin D, exacerbated
by decreased sun exposure if indoors due to poor health).Mutation
of the CFTR gene itself may have a direct role in the pathogenesis
of CF-related bone disease (Dif 2004).
The clinical consequences of CF-related bone disease include low
bone density with potential fractures, including rib and vertebral
fractures, whichmay be precipitated by coughing. A study in post-
lung transplant participants with CF found an approximate two-
fold increase in the risk of non-vertebral fractures for women aged
16 to 34 years (P = 0.015) and men aged 25 to 45 years (P = 0.04)
comparedwith the general population (Aris 1998). Vertebral com-
pression and rib fractures were 100-fold and 10-fold more com-
mon respectively than predicted (P < 0.001). Incident new verte-
bral fractures are commonly defined as a 15% or greater reduction
in anterior, posterior, or middle vertebral height. Acutely, vertebral
and rib fractures may result in pain and debilitation, resulting in
diminished lung function, ineffective cough and airway clearance,
limitations in respiratory physiotherapy, in addition to reduced
physical activity. Chronic consequences may include kyphosis and
chest wall deformities which may worsen lung function. Hence a
vicious cycle of further impairment in lung function and deterio-
ration in bone health may result (Aris 2005; Boyle 2006). Estab-
lished bone disease may exclude the patient from lung transplanta-
tion, as the high-dose corticosteroids and other immunosuppres-
sion required post-transplantation can be expected to worsen bone
disease further (Aris 1996).
Description of the intervention
Bisphosphonates are a class of drugs that inhibit bone resorp-
tion (Russell 2007). Considerations in using bisphosphonate ther-
apy include different formulations (oral, intravenous), dosage, fre-
quency of administration, intermittent versus continuous dosing
and duration of therapy (Russell 2006).
Potential side-effects include an acute-phase response leading
to fever and ’flu’-like symptoms (myalgia, malaise). This has
been most commonly observed after the first exposure to ni-
trogen-containing bisphosphonates administered intravenously,
and associated with an increase in inflammatory cytokines (Sauty
1996). Osteonecrosis of the jaw has been associated with high-
dose intravenous bisphosphonate therapy in patients with malig-
nancy (Pendrys 2008). Upper gastrointestinal side-effects (e.g. oe-
sophagitis) have been associated with oral agents (Cryer 2002).
How the intervention might work
Bisphosphonates are selectively taken up by bone and exert in-
hibitory effects on osteoclasts, cells that act to dissolve and resorb
bone (Russell 2007). Individuals drugs within this class have dif-
ferent mineral binding affinities and molecular modes of action
(e.g. nitrogen-containing pamidronate, alendronate, risedronate,
ibandronate and zoledronate are more potent than the non-nitro-
gen containing etidronate and clodronate) (Russell 2006).
Bisphosphonates have proven effective treatments for disorders of
excessive bone resorption: Paget’s disease of bone, myeloma, bone
metastases (Russell 2006); postmenopausal osteoporosis (Black
1996); other forms of osteoporosis (e.g. associated with glucocor-
ticoid administration (Saag 1998)); and children with the ’brittle
bone’ disorder, osteogenesis imperfecta (Glorieux 1998; Phillipi
2008). Positive outcomes have included increased bone mass,
BMD and a reduction in fracture frequency.
A two-year study of intermittent cyclical etidronate in 423 post-
menopausal women demonstrated a significant increase in BMD
at the spine and a decrease in new fractures (Watts 1990). In a
study of 2027 women with at least one existing vertebral fracture,
alendronate was shown to increase BMD at the spine and hip and
to decrease fractures at the hip, wrist and spine after three years
of treatment (Black 1996). Pamidronate in combination with cal-
cium was studied over an 18-month period in an initial cohort
of 35 postmenopausal women (mean age 64.5 years) with at least
one atraumatic vertebral fracture due to osteoporosis. After one
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year, BMD increased in the lumbar spine (P < 0.001), although
there were no changes in the femoral neck (Fromm 1991). Oral
risedronate has been observed to secondarily prevent vertebral and
non-vertebral fractures in postmenopausal women (Wells 2008).
A study of 477 participants with glucocorticoid-induced osteo-
porosis found alendronate to be highly effective in increasing
BMD at the spine and femoral neck, with a significant reduction
in the number of incident fractures (Saag 1998). Another one-
year study compared two regimens of intravenous pamidronate (a
single infusion or once every three months) for the primary pre-
vention of glucocorticoid-induced osteoporosis. The study popu-
lation consisted of 32 participants who required long-term gluco-
corticoid therapy with at least 10 mg of prednisone daily. A highly
significant difference was observed between both pamidronate reg-
imens and the control group at the lumbar spine (P < 0.001)
and femoral neck (P < 0.01). Both pamidronate regimens effec-
tively achieved primary prevention of glucocorticoid-induced os-
teoporosis (Boutsen 2001). This evidence is particularly promis-
ing since corticosteroid use is associated with osteoporosis among
people with CF.
A three-year randomized double-blind trial of 300 mg oral
pamidronate daily compared with placebo was conducted in 105
participants with rheumatoid arthritis. Inflammation, decreased
mobility and glucocorticoid use may contribute to the risk of os-
teoporosis in individuals with rheumatological conditions. After
three years, lumbar spine and forearm BMD had increased signif-
icantly in the pamidronate-treated group while there were non-
significant changes in the placebo-treated group. Changes were
significantly different between the treatment and placebo groups
(Eggelmeijer 1996).
Why it is important to do this review
A multi-faceted approach to the prevention and treatment of low
BMD has been recommended including optimising vitamin, cal-
cium and nutritional status, encouraging weight-bearing exercise,
endocrinological assessment and management of delayed puberty
or hypogonadism, aggressive treatment of pulmonary infections,
minimizing exposure to corticosteroids and treatment of CF-re-
lated diabetes (Aris 2005). A Consensus Statement addressing the
issue of bone health and disease in CF recommends consideration
of oral or intravenous bisphosphonates in individuals with DXA
T- or Z-scores ≤ 2.0, awaiting transplant or BMD loss more than
3 to 5% per year (Aris 2005). A caution is placed on the use of in-
travenous bisphosphonates due to the association with severe bone
pain in this population group. The Report of the UK Cystic Fi-
brosis Trust Bone Mineralisation Working Group (Cystic Fibrosis
Trust Report 2007) recommends consideration of bisphosphonate
treatment in adults who:
1. have sustained a fragility fracture;
2. have lumbar spine, total hip or femoral neck Z-scores ≤ -2
and there is evidence of significant bone loss (>4% per year) on
serial DXA measurements despite implementation of general
measures to improve bone health;
3. are starting a prolonged (greater than 3 months) course of
oral glucocorticoid treatment and have a BMD Z-score of ≤ -
1.5; or
4. are listed for or have received a solid organ transplant and
have a BMD Z-score of ≤ -1.5.
The report (Cystic Fibrosis Trust Report 2007) also states that
bisphosphonates may be beneficial in children
1. with a history of fragility fractures;
2. listed for or post transplantation; or
3. who have low BMD and continuing bone loss despite
implementing general measures for optimising bone health.
Hence, a review of the available evidence assessing bisphospho-
nates for osteoporosis in people with CF is important.
O B J E C T I V E S
To determine whether bisphosphonates cause the following
changes in people with CF:
1. decrease fractures (vertebral and non-vertebral);
2. improve BMD measured using DXA or, if available, using
other methods of bone density measurement such as single
energy X-ray absorptiometry (SXA) and quantitative
tomography (QCT);
3. increase quality of life;
4. increase adverse events, including bone pain and
gastrointestinal adverse events;
5. change the number of withdrawals due to all causes and due
to adverse events;
6. increase survival.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials. Published papers and abstracts were
included. Trials published in all languages were considered for
inclusion.
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Types of participants
People of all ages and of both sexes with CF diagnosed clinically
or by sweat and genetic testing, including all degrees of disease
severity and bone density.
Types of interventions
All trials examining bisphosphonates compared to controls (other
bisphosphonates, placebo or usual treatment) for treating or pre-
venting osteoporosis in people with CF were considered for inclu-
sion. All doses and routes of administration were considered. Tri-
als of a minimum duration of six months were included to allow
time to observe an effect of treatment.
Types of outcome measures
Primary outcomes
1. Fractures (number of participants with any fracture and
number of fractures at all sites, spine, hip, wrist)
Secondary outcomes
1. Bone density as measured by dual-energy X-ray
absorptiometry (DXA), reported as percent change from
baseline. Data reported using other methods of bone density
measurement such as single energy X-ray absorptiometry (SXA)
and quantitative tomography (QCT) would be used if available
but analysed separately:
i) lumbar spine
ii) hip or femur
iii) radius
iv) total body
2. Quality of life (CF-related, osteoporosis-related or general
QOL measures)
3. Adverse events such as bone pain, hypocalcaemia and
gastrointestinal adverse events (number of participants, number
of adverse events)
4. Withdrawals
i) Withdrawals due to adverse events
ii) Total withdrawals
5. Survival
Search methods for identification of studies
Electronic searches
Relevant trials were identified from the Group’s Cystic Fibrosis
Trials Register using the terms: osteoporosis OR pamidronate OR
alendronate OR risedronate OR etidronate OR zoledronate OR
clodronate OR ibandronate OR neridronate OR tiludronate OR
olpadronate OR medronate OR incadronate OR alpadronate.
The Cystic Fibrosis Trials Register is compiled from electronic
searches of the Cochrane Central Register of Controlled Trials
(Clinical Trials) (updated each new issue), quarterly searches of
MEDLINE, a search of EMBASE to 1995 and the prospective
handsearching of two journals - Pediatric Pulmonology and the
Journal of Cystic Fibrosis. Unpublished work is identified by search-
ing the abstract books of three major cystic fibrosis conferences:
the International Cystic Fibrosis Conference; the European Cystic
Fibrosis Conference and theNorth American Cystic Fibrosis Con-
ference. For full details of all searching activities for the register,
please see the relevant sections of the Cystic Fibrosis and Genetic
Disorders Group Module.
Date of the most recent search of the Group’s Cystic Fibrosis Trials
Register: 29 October 2008.
Additionally LC performed personal searches of PubMed on 01
November 2008 (all years up to 01 November 2008) (Appendix
1; Appendix 2).
Searching other resources
For the original review abstracts from amajor osteoporosis confer-
ence (The American Society for Bone and Mineral Research and
The Institute of Biomedical Science (ASBMR-IBM) 2nd Joint
Meeting 1998; ASBMR21st AnnualMeeting 1999)were searched
and also the reference lists from the retrieved articles.
In the update, the reference lists for the retrieved articles were
also searched and from that, a further paper (Conway 2004) was
identified.
Data collection and analysis
Selection of studies
In the original review, two authors (CB, AP) independently re-
viewed the trials in order to assess which trials should be included.
In this updated review (2009), two authors (LC, AC) indepen-
dently reviewed the trials included in the original review in ad-
dition to trials identified by the updated search. If there was dis-
agreement about whether a trial should be included, the authors
planned to ask an independent author from a third centre to review
the paper(s) in question. The authors documented the reasons for
excluding any trial.
Data extraction and management
In the original review, each author independently extracted data
for the outcome measures listed below. The review authors con-
tacted the first authors of the included trials to verify their data
and obtain unpublished data where necessary. Cochrane Review
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Manager (Version 4.1) was used to compile and analyse the data
(ReviewManager 2003). The authors compared their data and re-
solved differences by referring to the original article; they planned
to resolve any remaining differences with a third individual.
In this updated review (2009), the authors (LC, AC) reviewed tri-
als that satisfied the inclusion criteria and recorded the following
information when available: study setting; year of study; source of
funding; participant recruitment details (including number of eli-
gible participants); inclusion and exclusion criteria; randomisation
and allocation concealment method; numbers of participants ran-
domised; blinding (masking) of participants, care providers and
outcome assessors; dose and type of intervention; duration of ther-
apy; co-interventions; numbers of participants not followed up;
reasons for withdrawals from study protocol (clinical, side-effects,
refusal and other); side-effects of therapy; and whether intention-
to-treat analyses were possible. The review authors requested fur-
ther information from the two authors but no response was re-
ceived. Data were reported at time-points 6 months, 12 months
and annually thereafterwhich are appropriate time-points to assess
treatment effects on fracture frequency and duration. For percent
change in BMD, data were combined and reported for the end of
study as it is unknown what length of study is needed for effect of
treatment to be evident. The Cochrane Review Manager version
5.0 was used to compile and analyse the data (Review Manager
2008). Similarly, the authors compared their data and resolved
differences by referring to the original article.
Separate analyses were conducted for participants who had re-
ceived a lung transplant and for those who had not. At this stage,
the number of people with CF who have received other organ
transplants is small. Therefore, individuals with other organ trans-
plants were included in the analysis of participants with a lung
transplant, since they share a common risk factor for osteoporo-
sis, that is the long-term use of immunosuppressive agents which
lower BMD.
Assessment of risk of bias in included studies
The two authorswhoperformed the original review independently
assessed the quality of the trials using the system as described by
Jadad (Jadad 1996). If there was disagreement about whether a trial
should be included, or about the quality score it should receive,
the authors asked an independent author from a third centre to
review the paper(s) in question.
In this review update, the authors (LC, AB) independently as-
sessed the quality of the trials using the criteria described in
the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2008):
1. degree of blinding (of clinician or person delivering
treatment, of participant or of outcome assessor);
2. is attrition bias present i.e. use of intention-to-treat analysis?
3. randomisation process i.e. the generation of allocation
sequence;
4. allocation process i.e. quality of allocation blinding;
5. is selective reporting present?
The authors then related these to the potential risk of bias in a
trial as follows. If it was judged that the generation of allocation
sequence and its concealment to be adequate, the trial was deemed
to have a low risk of bias. If these criteria were judged to be inad-
equate, the risk of bias was judged to be high. Likewise, if a trial
was described as being double-blind and details were given as to
who was blinded, then the authors judged the trial to have a low
risk of bias. If a trial was not blinded, then it was judged to have
a high risk of bias. Finally, if incomplete outcome data had been
addressed, then the trial was judged to have a low risk of bias.
If these data were not addressed the trial was deemed to have a
high risk of bias. If there was insufficient information to make a
judgement on any of these criteria, the risk of bias for each one
was deemed to be unclear (Higgins 2008).
Measures of treatment effect
For the dichotomous outcome variables (adverse events, fractures,
survival) of each individual study, we calculated the odds ratio
(OR) using a modified intention-to-treat analysis (where incom-
plete data assumes failure of treatment). We also calculated the
summary odds ratios and 95% confidence intervals (CIs) using the
Cochrane Collaboration’s statistical package, RevMan 5 (Review
Manager 2008). It was planned that numbers needed to treat
(NNT) would be calculated from the pooled OR and its 95%
CI applied to a specified baseline risk, which is the sum of all
the events in the control groups (in all trials) divided by the total
participant numbers in control groups in all trials using an online
calculator (Cates 2003).
For continuous outcomes (changes in BMD and laboratory val-
ues), we recorded the mean relative change from baseline for each
group or mean post-treatment or post-intervention values and
standard deviation (SD). It was planned that when standard errors
are reported, we would calculate the SDs. We would then calcu-
late a pooled estimate of treatment effect by the mean difference
(MD) and 95% CIs again using the statistical package from The
Cochrane Collaboration (Review Manager 2008).
Unit of analysis issues
There were no cross-over studies, but if there had been, we planned
that only data from the first arm of the study would be used for any
analysis due to the potential for a carry-over effect.We would have
analysed count data of rare events as rates (number of counts to
the amount of time during which they could have happened). We
would have used the summary statistic rate ratio in meta-analysis.
For rate ratios of common events, whereby one participant may
have more than one event, we planned to use the generic inverse
variance (GIV) method of analysis.
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Dealing with missing data
We contacted primary authors to try and obtain missing data or
clarify data.
Assessment of heterogeneity
We planned to describe any heterogeneity between the study re-
sults and test it to see if it reached statistical significance using the
I2 statistic (Higgins 2003). This measure describes the percentage
of total variation across studies that are due to heterogeneity rather
than by chance (Higgins 2003).
The values of I2 lie between 0% and 100%, and a simplified
categorization of heterogeneity that we planned to use is of low (I2
value of 0-40%),moderate (I2 value 30-60%), substantial (I2 value
50-90%) and considerable (75-100%) (Higgins 2008). Strength
of evidence for heterogeneity was also indicated by the P value
from the chi-squared test, considered to be statistically significant
when the P value was less than 0.10 (Higgins 2005).
Assessment of reporting biases
In order to identify selective reporting, we compared outcome
measures reported within the published papers to the measures
described in the methodology sections or with the study protocols
if they were available.
Data synthesis
We included the results from studies that met the inclusion criteria
and reported any of the outcomes of interest in the subsequent
meta-analyses using a fixed-effect model. We would have included
the 95% CI, estimated using a random-effects model if there was
heterogeneity of moderate or greater (I2 > 30%).
If studies reported outcomes using different measurement scales,
we planned to estimate the standardised mean difference.
Subgroup analysis and investigation of heterogeneity
We planned to analyse the trials in the subgroups of children (aged
18 years or less) and adults (over 18 years). There were no trials
fulfilling the definition of the former subgroup, but this planned
subgroup analysis will be carried out if a sufficient number of
relevant trials (at least 10) are included in a future update of this
review.
Sensitivity analysis
We had also planned to conduct sensitivity analyses to assess the
impact of the potentially important factors on the overall out-
comes:
1. differences in the medications used in the intervention and
comparison groups;
2. analysis using random effects model;
3. analysis by “treatment received”; and
4. analysis by “intention-to-treat”.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of studies awaiting classification.
Results of the search
Seven clinical trials were identified that were all published in En-
glish (Aris 2000; Aris 2004; Boyle 2005; Chapman 2008; Conway
2004; Hardin 2005; Haworth 2001). Five trials were identified
from the search of the Group’s Cystic Fibrosis Trials Register (Aris
2000; Aris 2004; Boyle 2005; Haworth 2001; Hardin 2005). Ad-
ditional PubMed searches as detailed in the appendices (Appendix
1; Appendix 2) identified two trials (Chapman 2008; Papaioannou
2008). Searching the reference lists for the retrieved articles iden-
tified a further trial (Conway 2004).
Five clinical trials were included and two were excluded (see be-
low). One trial is currently listed as awaiting clarification and will
be either included or excluded in the next update of this review
(Papaioannou 2008).
Included studies
Five clinical trials met the inclusion criteria for this review (Aris
2000; Aris 2004; Boyle 2005; Chapman 2008; Haworth 2001).
One trial was published only as an abstract; we contacted the lead
investigator for details of the full publication, but have received no
reply (Boyle 2005). Three trials were published both as abstracts
and full review papers (Aris 2000; Aris 2004; Haworth 2001).
One trial was published as full review paper (Chapman 2008).
All the trials had similar designs, duration of planned interven-
tion (12 to 24 months) and outcome measures. None of the trials
reported sample size or power calculations. None of the studies
included children (aged 18 years or less). In the Boyle trial, en-
rolment was ceased after five participants were randomised and
follow-up duration was decreased from 12 months (to six months
due to adverse events i.e. musculoskeletal pain) (Boyle 2005). The
follow-up duration of the trial assessing intravenous pamidronate
was also shortened from 12 months to 6 months due to adverse
events i.e. bone pain (Aris 2000). One trial assessed 24 months
of intravenous pamidronate in 34 post-transplant adults with CF
(Aris 2000). The participants in the other four trials were non-
transplanted adults with CF. Other factors that will contribute to
the heterogeneity in the results of the review include differences
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in trial populations and concomitant general health, activity levels
and medications (prednisone, cyclosporin A, azathioprine in the
transplant group).
Funding for one trial was provided by grants from the CF Foun-
dation and the Verne S. Caviness General Center for Clinical Re-
search (Aris 2000). Another trial was funded by the U.S. Food and
Drug administration, Merck and Co, Inc., the Clinical Nutrition
Research Unit, the Verne S. Caviness General Center for Clinical
Research at University of North Carolina, the CF Foundation and
the NIDDK (Aris 2004). Novartis Pharmaceuticals Pty Ltd, Aus-
tralia partly funded one trial (Chapman 2008). Haworth and col-
leagues received funding from the CF trust in the UK (Haworth
2001).
All participants in four of the trials received supplemental cal-
cium and vitamin D (Aris 2000; Aris 2004; Boyle 2005; Chapman
2008). In the study by Haworth and colleagues, participants with
pancreatic insufficiency were prescribed long-term oral vitamin D
supplements (all participants except one participant in the control
group) (Haworth 2001). Oral prednisolone was administered to
all participants of one study for three days starting on the morn-
ing of the first infusion (Chapman 2008). This was repeated with
subsequent infusions if a reaction to the first infusion was thought
likely. The types of bisphosphonate assessed in the trials included
intravenous pamidronate in two trials, 31 participants in the Ha-
worth trial and 34 participants in the earlier Aris trial (Aris 2000;
Haworth 2001), oral alendronate (53 participants) (Aris 2004),
intravenous zoledronate (22 participants) (Chapman 2008) and
intravenous zoledronate (40 participants planned) (Boyle 2005).
Excluded studies
Two clinical trials were excluded (Conway 2004; Hardin 2005).
One trial was a prospective open study assessing the effect of oral
bisphosphonates on BMD and body composition in adults with
CF (Conway 2004). It was not a randomised controlled trial.
The other trial assessed the effect of growth hormone on bone
mineral content in children with CF (Hardin 2005). It did not
assess the use of bisphosphonates and hence did not meet the
inclusion criteria for this review.
Risk of bias in included studies
For detailed information on the risk of bias of each included trial,
please refer to the risk of bias tables attached to the ’Characteristics
of included studies’ section of this review.
Allocation
All trials stated that allocation was in accordance to randomisa-
tion. Two trials described a “blocks of four” design, but the actual
method of randomisation was not discussed. We judged the risk
of bias due to the generation of the randomisation sequence as
unclear (Aris 2000; Aris 2004). In the other trials, the method of
randomisation and hence the risk of bias was also unclear (Boyle
2005; Chapman 2008; Haworth 2001).
Concealment of allocation and hence risk of bias was unclear in
all five trials (Aris 2000; Aris 2004; Boyle 2005; Chapman 2008;
Haworth 2001).
Blinding
Clinician or person delivering treatment
In one trial, clinicians giving the interventions were not blinded
(Aris 2000); and in another, thiswas not reported (Haworth 2001).
The remaining trials were described as “double-blind”, but the
blinding of those delivering treatment was not specifically dis-
cussed (Aris 2004; Boyle 2005; Chapman 2008).
Participants
In one trial, participants were not blinded to the treatment group
(Aris 2000); in another, this was not reported (Haworth 2001).
Participants were blinded to the intervention group in the other
three trials, which we therefore judged to have a low risk of bias
(Aris 2004; Boyle 2005; Chapman 2008).
Outcome assessors
In one trial, only the radiologist who interpreted the DXA scans
was blinded (Aris 2000). In one trial, it was stated that the person-
nel who performed and analysed the DXA scans were blinded to
the treatment group, but it was not clear whether all the outcome
assessors were blinded (Chapman 2008). In one trial, blinding was
not reported (Haworth 2001) and the other two trials were de-
scribed as “double-blind” although it was not specifically discussed
whether all the outcome assessors were blinded (Aris 2004; Boyle
2005).
Hence considering these different types of participants and per-
sonnel together, there was a risk of bias in all the trials (Aris 2000;
Aris 2004; Boyle 2005; Chapman 2008; Haworth 2001).
Incomplete outcome data
All five trials describedwithdrawals from treatment. Further details
can be found in the ’Risk of bias’ tables in Characteristics of
included studies (Aris 2000; Aris 2004; Boyle 2005; Chapman
2008; Haworth 2001).
In one trial, five withdrawals between commencement of protocol
and outcomes measured at six months were described, but not
delineated as to whether they were in the treatment or the control
group (Aris 2004). Hence the risk of bias was unclear. In another
trial, it was unclear which specific participants had BMD mea-
surements available at each time-point, particularly for forearm
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measures (fewer measurements compared with lumbar spine and
femoral neck) (Chapman 2008).
Withdrawal rates and hence risk of attrition bias varied. For ex-
ample, from protocol commencement to BMD (lumbar spine)
measurement at end of study, total withdrawals were 13/53 (25%)
(Aris 2004), 3/22 (14%) (Chapman 2008), 3/31 (10%) (Haworth
2001) and 0/34 (0%) (Aris 2000).
Selective reporting
Outcome measures described in the methodology were reported
for most trials (Aris 2004; Chapman 2008; Haworth 2001), hence
a low risk of bias. The exception was the serum and urine bio-
chemical measurements at +2 days (only after first pamidronate
infusion in intervention group) which were not reported in one
trial (Aris 2000).
Effects of interventions
Five trials were included, four examined participants who had
not undergone lung transplantation (Aris 2004; Boyle 2005;
Chapman 2008; Haworth 2001); the other studied participants
received lung transplants (Aris 2000). All participants were adults.
Trial of participants who have not received lung
transplant
Primary outcome
1. New Fractures
Combining data from two trials for vertebral fractures at the 12
month time-point; there were no vertebral fractures reported for
either group (20 participants in each) in the trial assessing 10
mg daily of oral alendronate (Aris 2004) or for either group (10
participants in each) in the trial assessing intravenous zolendrate
every three months (Chapman 2008). At the 24-month time-
point, only data from the Chapman trial are available and these
do not show any vertebral fractures in either treatment or control
group (Chapman 2008). Please refer to Analysis 1.1.
Data from the two trials which reported non-vertebral fractures
could be combined at 12 months (Aris 2004; Chapman 2008).
There was no statistically significant difference in the number
of participants with new non-vertebral fractures in the treatment
group compared to controls, OR 2.11 (95% CI 0.18 to 25.35)
(Analysis 1.2). In the Aris trial, 2 out of 20 participants in the alen-
dronate group reported fractures (arm and rib) compared to 1 out
of 20 participants in the control group (toe fracture) (Aris 2004);
there were no reported fractures in the Chapman trial (Chapman
2008). Neither did Chapman report any fractures in either group
at 24 months (Chapman 2008).
Combining data for both vertebral and non-vertebral fractures
from the available studies (Analysis 1.3), there was no significant
difference between groups, OR 2.11 (95% CI 0.18 to 25.35).
Fractures were not reported as an outcome measure in the other
two trials; we contacted the authors to clarify if these had been
measured in the trials, but have not received a reply (Haworth
2001; Boyle 2005).
Secondary outcomes
1. Per cent change in BMD
a. Lumbar spine
We have presented individual time-points (Analysis 1.4) and sum-
mary end of study data (Analysis 1.5).
All four studies reported on this outcome (Aris 2004; Boyle 2005;
Chapman 2008; Haworth 2001).
At the six-month time-point, data from the four studies showed
there was a significant increase in BMD measured at the lum-
bar spine in the treatment group, MD 4.61 (95% CI 3.90 to
5.32) (Aris 2004; Boyle 2005; Chapman 2008; Haworth 2001)
(Analysis 1.4). In the study by Aris, participants receiving oral al-
endronate had increased lumbar spine BMD after six months of
the intervention; lumbar spine BMD decreased in control group
participants at this time-point (Aris 2004). The MD for percent
change BMD at the lumbar spine after six months was 5.50 (95%
CI 4.11 to 6.89) (Aris 2004). The Boyle trial was ceased after
only five participants were enrolled (three in the treatment group),
the mean (SD) lumbar spine BMD had increased by 4.7 (0.6)%
six months after the single dose of intravenous zoledronate com-
pared to no change in the two participants in the placebo group
(Boyle 2005). In the second study, intravenous zoledronate was
associated with a statistically significant positive effect on BMD at
the lumbar spine after six months of treatment (Chapman 2008).
The MD for percent change BMD for the lumbar spine at six
months was 4.16 (95% CI 3.30 to 5.02) (Chapman 2008). In the
Haworth study, after six months intravenous pamidronate inter-
vention, participants in the control group had decreased lumbar
spine; participants in the treatment group had gained BMD in
this region (Haworth 2001). The MD for percent change lum-
bar spine BMD at six months was 5.80 (95% CI 2.91 to 8.69)
(Haworth 2001). There was low statistical heterogeneity between
studies; I2 = 39% at the six-month time-point.
Only two studies had data available at the 12-month time-point
(Aris 2004; Chapman 2008) (Analysis 1.4). These combined data
showed a significant increase in BMD in favour of pamidronate,
MD 6.38 (95%CI 5.21 to 7.54). In the study by Aris, participants
9Bisphosphonates for osteoporosis in people with cystic fibrosis (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
in the treatment group had increased lumbar spine BMD after
12 months of the intervention. This decreased in control group
participants at this time-point (Aris 2004). The MDs for percent
change BMD at the lumbar spine after 12 months was 6.70 (95%
CI 4.51 to 8.89) (Aris 2004). In the Chapman study, the inter-
vention showed a statistically significant positive effect on BMD
at the lumbar spine after 12 months of treatment, MD 6.25 (95%
CI 4.88 to 7.62) (Chapman 2008). At this 12-month time point,
there was also low statistical heterogeneity between studies; I2 =
0% (Analysis 1.4).
Only Chapman reported 24-month data for lumbar spine BMD
and this result too was significant in favour of the treatment group,
MD 5.70 (95% CI 4.55 to 6.85) (Chapman 2008) (Analysis 1.4).
Pooling end of study results for trials assessing intravenous bispho-
sphonates, there were positive BMD effects at the lumbar spine,
MD 5.90 (95% CI 4.94 to 6.87) (Analysis 1.5). There was no sta-
tistical heterogeneity between studies for lumbar spine BMD (I2
= 0%) (Aris 2004; Boyle 2005; Chapman 2008; Haworth 2001).
b. Total hip or femur
Three studies reported on this outcome (Aris 2004; Chapman
2008; Haworth 2001). We have presented individual time-points
(Analysis 1.6) and summary end of study data (Analysis 1.7).
Combined data at six months showed a significant result in favour
of bisphosphonates for total hip or femur BMD, MD 3.35 (95%
CI1.63 to 5.07) (Analysis 1.6). In theAris trial, participants receiv-
ing oral alendronate had increased total hip or femur BMD after
six months of the intervention; but this outcome was unchanged
in the control group at this time, MD 2.20 (95% CI 0.81 to 3.59)
(Aris 2004). Chapman reported that intravenous zoledronate was
associated with a statistically significant positive effect on BMD at
the total hip or femur regions after six months of treatment, MD
4.63 (95% CI 3.49 to 5.77) (Chapman 2008). In the Haworth
trial, after the six months intravenous pamidronate intervention,
participants in the control group had decreased total hip or femur
BMD; participants in the treatment group had gained BMD in
this region, MD 3.00 (95% CI 0.60 to 5.40) (Haworth 2001).
Data from two trials were combined at the 12-month time-point
and again showed a significant increase in total hip or femur BMD,
MD 4.84 (95% CI 2.73 to 6.96) (Analysis 1.6). At 12 months,
participants in the Aris trial receiving oral alendronate had in-
creased total hip or femur BMD but this decreased compared to
baseline in the control group, MD 3.50 (95% CI 1.01 to 5.99)
(Aris 2004). Chapman reported a statistically significant positive
effect on BMD at the total hip or femur regions in the zolendrate
group after 12 months of treatment, MD 5.71 (95% CI 4.25 to
7.17) (Chapman 2008).
OnlyChapman reported data for the 24-month time-point, which
was again significant in favour of the intervention, MD6.73 (95%
CI 5.51 to 7.95) (Analysis 1.6)
Pooling end of study results for trials assessing intravenous bis-
phosphonates, there were positive BMD effects at the total hip
or femur, MD 4.58 (95% CI 1.92 to 7.24) (Analysis 1.7). While
there was no statistical heterogeneity between studies for lumbar
spine BMD, that for total hip or femur was significant (I2 = 73%
at six months and I2 = 56% at 12 months) (Aris 2004; Chapman
2008; Haworth 2001).
c. Radius
Please refer to Analysis 1.8, Analysis 1.9 and Analysis 1.10.
Two studies reported data for distal radius (Chapman 2008;
Haworth 2001) and one reported data for ultradistal radius
(Haworth 2001).
Combined data for distal radius at the six-month time-point do
not show a significant result, MD -0.49 (95% CI -2.42 to 1.45).
In the Chapman study, distal radial BMD was not statistically
different from the control group at six months, MD 0.32 (95%CI
-0.50 to 1.14). In the Haworth study, there was a non-significant
decrease in BMD as measured by SXA of the distal forearm, MD
-1.70 (95% CI -3.66 to 0.26) (Analysis 1.8).
Only Chapman reported data for the 12-month and 24-month
time-points. At 12 months, distal radial BMDwas not statistically
different from the control group, MD 0.32 (95% CI -0.30 to
0.94). However, at 24 months, this was significant in favour of
bisphosphonates, MD 1.50 (95% CI 0.41 to 2.59) (Chapman
2008).
As is the case for total hip or femur, there was significant statisti-
cal heterogeneity between studies for distal radius (I2= 71% at 6
months).
In theHaworth study, measurements of appendicular sites showed
opposite trends. There was a non-significant decrease in BMD as
measured by SXA of the ultradistal forearm in participants receiv-
ing pamidronate at six months, MD -2.70 (95%CI -5.59 to 0.19)
(Haworth 2001) (Analysis 1.10).
2. Quality of life
No quality of life measurements were reported (Aris 2004; Boyle
2005; Chapman 2008; Haworth 2001).
3. Adverse events
All four studies reported on adverse events (Aris 2004; Boyle
2005; Chapman 2008; Haworth 2001). We were able to present
combined data in a meta-analysis for bone pain (Analysis 1.11)
and for fever (Analysis 1.12).
a. Bone Pain
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In the study of oral bisphosphonates, none of the participants in
either the intervention or the control group experienced bone pain
(Aris 2004).
Pooling the results for intravenous bisphosphonates, including the
study in which participants received oral prednisone daily for three
days on themorning of the first infusion (repeatedwith subsequent
infusions if a reaction to the first infusion was thought likely), the
occurrence of bone pain was significantly higher in participants in
the treatment groups (18 out of 28) compared to control groups
(2 out of 32), OR 14.17 (95% CI 3.64 to 55.17) (Boyle 2005;
Chapman 2008;Haworth 2001). Boyle reported that three partic-
ipants experienced dramatic musculoskeletal pain, two requiring
emergency room assessment. Symptoms began six to eight hours
after infusion, peaked at 12 to18 hours, and were characterized by
severe chest and back pain. Although the most severe symptoms
resolved within 48 to 72 hours, participants reported continued
arthralgias for up to a week. It was presumed that these three par-
ticipants were those in the treatment group (no reply was received
to an attempt to contact the author) (Boyle 2005). Chapman re-
ported that there was no significant difference between treatment
and control groups with respect to musculoskeletal pain (4 out of
10 in the zoledronate group, 2 out of 12 in the control group), OR
3.33 (95%CI 0.46 to 24.05) (Chapman 2008). In the Haworth
trial, no participants in the control group experienced bone pain;
but 11 out of 15 participants in the treatment group experienced
moderate to severe pain following the first dose of medication, OR
94.56 (95% CI 4.65 to 1924.08). Nine participants reported se-
vere bone pain. The pain was reported to be excruciating in seven
participants rendering them bed bound and making sputum ex-
pectoration and physiotherapy difficult. None of the participants
experiencing bone pain were taking corticosteroids, while three of
the four participants without bone pain in the treatment group
did (Haworth 2001).
b. Fever
In the study of oral bisphosphonates, none of the participants in
either the intervention or the control group experienced fever (Aris
2004).
Combined data from the trials of intravenous bisphosphonates
show participants in the treatment groups were significantly more
likely to experience fever,OR12.64 (95%CI2.31 to 69.11) (Boyle
2005; Chapman 2008; Haworth 2001). Boyle reported that one
participant experienced a fever of 1040F lasting for several hours
and a rise in Tumour Necrosis Factor-α, OR 3.00 (95%CI 0.08 to
115.34) (Boyle 2005). In the Chapman trial the number of partic-
ipants experiencing fever was significantly higher in the treatment
group (8 out of 10 in the zoledronate group, 1 out of 12 in the
control group), OR 44.00 (95% CI 3.38 to 573.41) (Chapman
2008). Haworth reported that two of the nine participants in the
treatment group had febrile reactions, OR 6.74 (95% CI 0.29 to
154.26) (Haworth 2001).
c. Other adverse events
In the Aris study, three cases of diarrhoea were reported; one par-
ticipant was receiving alendronate and two were receiving placebo.
This was accompanied by abdominal cramping and loss of ap-
petite. These participants continued to experience diarrhoea after
discontinuing the study medication (Aris 2004).
Chapman reported that musculoskeletal side effects were experi-
enced following 27 of 63 zoledronate infusions, but after only 4 of
73 placebo infusions. This was despite administering prednisolone
to all participants with at least the first infusion, and these side
effects were more common after the first than the subsequent in-
fusions. In six participants, the reactions were described as severe,
in two cases resulting in withdrawal. One of these participants re-
quired admission to hospital with severe pain and fever restricting
movement, with onset 12 hours after the first infusion; this re-
solved after four days, but led to subsequent withdrawal from the
study. The other participant experienced fever, rigor, bone pain
and headache 24 hours after the first infusion with resolution in
five days. Similar effects were experienced after the second infu-
sion followed by study withdrawal (Chapman 2008).
Haworth reported that one participant developed phlebitis around
the infusion site (Haworth 2001).
None of the studies assessed calcium levels post-intravenous bis-
phosphonate infusion (Boyle 2005; Chapman 2008; Haworth
2001).
4. Withdrawals
We have presented data for withdrawals due to adverse events
(Analysis 1.13) and total withdrawals (Analysis 1.14).
Three studies described withdrawals from the study. At 6, 12 and
24 months, data from these three trials do not show any signif-
icant difference between treatment or control groups for with-
drawals due to adverse events or in total for any reason (Aris 2004;
Chapman 2008; Haworth 2001).
In the Aris study, of the 53 participants who started the protocol,
five dropped out in the first six months. The reasons included
pregnancy (n = 1, experienced a spontaneous abortion in her first
trimester), dysphagia (n = 1, experienced difficulty swallowing the
first tablet and had similar difficulties swallowing other medica-
tions), and diarrhoea (n=3). For the first two participants, it was
unclear which group they were allocated to. One of the partici-
pants experiencing diarrhoea was receiving alendronate and two
were receiving placebo. No participants withdrew due to gastroin-
testinal reflux symptoms. Of the 48 participants who completed
DXA assessment at sixmonths beyond baseline, 4 out of 24 in each
group withdrew before the DXA assessment at 12 months beyond
baseline. In the treatment group, the withdrawals were due to lung
transplantation (n = 1), moving (n = 2) and non-compliance (n =
1); in the control group these were due to lung transplantation (n
= 2), death (n = 1) and moving (n = 1) (Aris 2004).
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At 24months Chapman reports there was no significant difference
between intravenous zoledronate and control groups with respect
to total withdrawals (3 out of 10 in the treatment group, 6 out
of 12 in the control group), OR 0.43 (95% CI 0.07 to 2.50) or
withdrawals due to adverse events (2 out of 10 in the treatment
group, 0 of 12 in the treatment group), OR 7.35 (0.31 to 173.13).
The adverse events have beendescribed previously. Thewithdrawal
thatwas unrelated to adverse events in the treatment groupwas due
to loss to follow-up. The six withdrawals in the control group were
due to loss to follow-up (n = 1), decreased BMD to withdrawal
threshold (n = 3), poor compliance to study requirements (n = 1)
and a combination of the latter two reasons (n = 1) (Chapman
2008).
Haworth also reports no significant difference between intra-
venous pamidronate and control groups with respect to total with-
drawals (2 out of 15 in the pamidronate group, 1 out of 16 in
the control group), OR 2.31 (95% CI 0.19 to 28.47). One par-
ticipant from each group died, while a second participant in the
pamidronate group withdrew in order to receive a double lung
transplant. No participant withdrew due to other adverse events
(Haworth 2001).
5. Survival
We have presented data on this outcome in Analysis 1.15.
Of the 48 participants in the oral alendronate trial who completed
DXA assessment at six months beyond baseline, one participant
of 24 in the control group died during the latter six months of the
study compared to none in the treatment group. This difference
was not statistically significant, OR 0.32 (95% CI 0.01 to 8.25)
(Aris 2004).
Two of the trials reported there were no deaths in either the treat-
ment or control group (Boyle 2005; Chapman 2008).
Haworth reported that intravenous pamidronate treatment did
not significantly affect survival compared with the control group
(14 out of 15 survivors in the pamidronate group, 15 out of 16 in
the control group), OR 0.93 (95% CI 0.05 to 16.39) (Haworth
2001).
Trial of participants who have received lung transplant
Primary outcome
1. New fractures
Please refer to Analysis 2.1, Analysis 2.2 and Analysis 2.3.
There was no statistically significant difference in the number of
participants with new vertebral fractures in the bisphosphonate
(pamidronate) group (3 out of 16 participants) versus the control
group (1 out of 18 participants), OR3.92 (95%CI 0.36 to 42.20).
There was also no statistically significant difference in the number
of participants with new non-vertebral fractures in the treated
(3 out of 16 participants) versus the untreated group (6 out of
18 participants), OR 0.46 (95% CI 0.09 to 2.27) (Aris 2000).
Considering any fractures, there was also a non-significant result,
OR 0.94 (95% CI 0.24 to 3.77) (Aris 2000).
Secondary outcomes
1. Percent change in BMD
Please refer to Analysis 2.4 and Analysis 2.5.
a. Lumbar spine
At the end of two years, the percent change in BMD was signifi-
cantly higher in the treatment group than in the control group at
the lumbar spine, MD 6.20 (95% CI 4.28 to 8.12) (Aris 2000).
b. Hip or femur
Likewise, at the end of two years, the percent change in BMD
was significantly higher in the treatment group than in the control
group at the femur,MD7.90 (95%CI 5.78 to 10.02) (Aris 2000).
2. Quality of life
No quality of life measurements were reported (Aris 2000).
3. Adverse events
Please refer to Analysis 2.6.
None of these participants, all of whom were receiving corti-
costeroids, experienced any bone pain (Analysis 2.6). Partici-
pants were assessed 24 hours post-infusion for cellulitis, throm-
bophlebitis, or fever; no cases were detected. Twenty-four hours
later, serum calcium, phosphorus, and magnesium and a complete
blood count were analysed. The study authors reported that there
were no significant differences compared with pre-infusion data,
with no episodes of hypocalcaemia and three episodes of mild hy-
pervitaminosis D that resolved spontaneously. The trial in post-
transplant participants also reported that there was no significant
difference in the degree of immunosuppression between the treat-
ment and control groups (Aris 2000).
4. Withdrawals
Please refer to Analysis 2.7 and Analysis 2.8.
There were no withdrawals other than those due to death in either
treatment group (Aris 2000).
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5. Survival
Please refer to Analysis 2.9.
Three participants died before the first BMD data could be col-
lected at six months; these participants were excluded from further
analysis and thus cannot be included as data in this review. The
authors stated that the exclusion of these three participants did not
significantly affect the subsequent analysis. No other participants
died during the course of the trial (Aris 2000).
Sensitivity analysis
a. Differences in the medications used in the intervention
and comparison groups
Considering non-transplanted participants, the differences in ad-
verse events between oral and intravenous bisphosphonates have
been described. The percent increase in BMD at the lumbar spine
still increased significantly at six months when oral bisphospho-
nates were analysed separately to intravenous bisphosphonates;
oral bisphosphonates, MD for percent change 5.50 (95% CI 4.11
to 6.89) (Aris 2004), intravenous bisphosphonates, MD 4.29
(95% CI 3.47 to 5.12) (Boyle 2005; Chapman 2008; Haworth
2001). This was also observed for the effect on lumbar spine BMD
(end of study) and hip or femur BMD (six months and end of
study).
b. Analysis using random-effects model
Using the random-effects model, the MD results for percent in-
creases in BMD for lumbar spine were still significant at the six
month time-point, MD 4.81 (95% CI 3.75 to 5.88) (Analysis
1.4).
c. Analysis by “treatment received”
Due to the lack of data, this was not possible.
d. Analysis by “intention-to-treat”
Due to the lack of data, this was not possible.
D I S C U S S I O N
Four studies investigated the effect of bisphosphonates in adults
with CF who had not undergone lung transplantation (Aris 2004;
Boyle 2005; Chapman 2008; Haworth 2001). One study assessed
this in adults with CF who had undergone lung transplanta-
tion (Aris 2000). Oral and intravenous bisphosphonates increased
BMD in adults with CF. However, severe bone pain and flu-like
symptoms were common with intravenous agents, especially in
participants not taking glucocorticoids. A reduction in fracture
rate was not observed.
Based on data from a single trial, the oral bisphosphonate, alen-
dronate was associated with increased BMD at the lumbar spine
and hip regions in adults with CF who had not undergone lung
transplantation (Aris 2004). Three other trials assessing differ-
ent bisphosphonate regimens (agent, duration and frequency) in
this population group also showed improved lumbar spine BMD
(Boyle 2005; Chapman 2008; Haworth 2001). Both trials with
hip or femur BMD as a measure showed positive effects on this
outcome (Chapman 2008; Haworth 2001). The two studies that
assessed radial BMD had conflicting results. Radial BMD was
significantly improved in the zoledronate study of duration 24
months (Chapman 2008), but not in the pamidronate study with
six months follow-up (Haworth 2001).
Lumbar spine and hip BMD were also improved by intravenous
pamidronate in a single trial in adult CF participants post-lung
transplantation (Aris 2000).
These trials provide valuable data on two different populations;
adults with CF who have received a transplant and those who
have not. Although the inclusion criteria, duration of follow up
and the magnitude of effect were different for the trials, similar
trends for BMD effect were seen, suggesting that the beneficial
effects of bisphosphonates might be generalisable to a fairly broad
population of people living with CF.
Bone mineral density is only an intermediate outcome. The more
clinically important endpoint is the occurrence of new fractures.
There was no significant effect of treatment on fractures (total,
vertebral or non-vertebral) in participants with or without lung
transplantation (Aris 2000; Aris 2004; Chapman 2008).
Bone pain, fever and gastro-oesophageal symptoms were not re-
ported in the oral bisphosphonate trial (Aris 2004). Participants
who did not receive corticosteroids during the clinical trial of in-
travenous pamidronate were more likely to experience bone pain
(Haworth 2001). The observed relationship between the regu-
lar use of glucocorticoid therapy and lack of bone pain may be
explained by evidence that corticosteroids suppress the release
of TNF-alpha (Steer 1997), an inflammatory cytokine known
to increase bone resorption. Haworth and his colleagues suggest
that bone pain may be avoided by prescribing a short course of
oral corticosteroids before and at the time of pamidronate infu-
sion (Haworth 2001). Zoledronate, a more potent bisphospho-
nate than pamidronate was associated with severe musculoskeletal
pain resulting in discontinuation of one trial early in enrolment
(Boyle 2005). In a subsequent study of intravenous zoledronate,
participantswere prescribeddaily prednisolone for three days com-
mencing on the day of the first infusion (and repeated if thought
necessary with subsequent infusions). Musculoskeletal pain was
not significantly increased in the treatment group. However, fever
and other flu-like effects were more commonly reported, severe
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in some participants, although the majority continued treatment.
The authors proposed that a longer period of treatment with cor-
ticosteroids, including pre-treatment dosing may diminish such
adverse effects (Chapman 2008). A Consensus Statement has rec-
ommended pre-treatmentwith oral corticosteroids for three to five
days prior to bisphosphonate infusion, but this has not been stud-
ied in an RCT (Aris 2005). None of the participants in the lung-
transplanted group, all of whom were receiving corticosteroids,
experienced any bone pain.
There was no significant effect of treatment on withdrawals or
survival. The lack of significant differences in the rate of fractures,
withdrawals or survival may related to the small numbers of par-
ticipants involved and the short duration of the trials
The risk of bias in the trials due to blinding was judged as present
(Aris 2000) or unclear (Aris 2004; Boyle 2005; Chapman 2008;
Haworth 2001). When participants are aware of the treatment
they are receiving, theymay be more or less likely to report adverse
events. The judgment of individuals who collect and interpret
patient data may be affected when the assessor is aware of the
treatment a participant is receiving. Lack of blinding may result
in biased results.
It was not possible to evaluate changes in quality of life since none
of the trials measured this variable.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Based on five small trials, oral and intravenous bisphosphonates
cause a rapid increase in spine and hip or femoral BMD in adults
with CF. Only two trials assessed the effect on distal radial BMD,
with only the study of longer duration reporting an improvement.
Severe bone pain is common with the use of intravenous bisphos-
phonates in participantswithCFnot receiving oral corticosteroids,
and may limit tolerability. These short-term trials (maximum of
two years) did not show fracture reduction or survival benefit.
Currently, no other options for the treatment of CF-related osteo-
porosis have been reported in the public domain. Thus, although
bisphosphonates increase BMD, no recommendation can bemade
concerning the use of bisphosphonates in participants with CF as
an effect on fractures could not be demonstrated.
Implications for research
This area of research would benefit from a large multicentre RCT
of bisphosphonates (oral and intravenous) with separate analyses
for participants with and without lung transplantation to measure
the effectiveness of these therapies on outcomes important to peo-
ple with CF, such as fractures and survival. These outcomes would
require long-term studies. Data on adverse events such as bone
pain and fever, in addition to the use of corticosteroids should also
be recorded. Studies assessing pre-treatment with corticosteroids
are required.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Aris 2000
Methods Randomised controlled trial, parallel design, trial duration 2 years.
Randomised in a “blocks of four” design, stratified on basis of gender and severity of
osteoporosis using spine z-score of -3.0;
Participant and provider not blinded, not all outcome assessors were blinded, only the
radiologist who interpreted the DXA scans;
Generation of allocation sequence was stated (“blocks of four” design). Allocation con-
cealment was unclear;
3 participants died during the course of the study, before the first primary end point
measurement, and were excluded from the analyses, including the final analysis of base-
line characteristics. The causes of death were one each from sepsis, acute respiratory dis-
tress syndrome and obliterative bronchiolitis. It was not reported whether they received
intervention;
Participants Single centre, university hospital, USA;
Inclusion criteria:- CF, 1 to 12 months post-lung transplantation, ambulatory;
Exclusion criteria:- primary graft failure or other post-operative morbidities that pre-
cluded long-term survival, renal insufficiency (serum creatinine > 3.0 mg/dl), or preg-
nancy;
N = 34 (16 in treatment group); 17 female (7 in treatment group).
Treatment group: mean (SD) age 27.5 years (6.6 years); control group mean (SD) age
29.1 years (6.4 years)
Groups similar in age, gender, baseline T-scores, renal function, hospitalisation rates,
immunosuppressant levels, change in lung function and body mass index over study
period
13 in treatment group and 12 controls had baseline T-scores < -2.5 at a minimum of
one site; all others -1 < T < -2.5 at a minimum of one site
Interventions Intravenous pamidronate (30 mg every 3 months) for study duration of 2 years;
All participants received oral vitamin D (800IU/day) and oral calcium (1g/day)
Outcomes Primary outcome:
BMD (spine; 0, 6, 12, 18, 24 months; DXA Hologic QDR 1000/W Waltham MA)
Secondary outcomes:
BMD (femur; 0, 6, 12, 18, 24 months; DXA Hologic QDR 1000/W Waltham MA);
New fractures (number of fractures during study; long bone using clinical data, rib using
posteroanterior chest radiographs, vertebral using lateral chest radiographs);
Kyphosis angles (degrees; 0, 24 months; thoracic spine curvature using lateral chest
radiographs using a modification of method of Cobb);
Adverse events (number during study; thrombophlebitis, cellulitis, bone pain, fever,
hypocalcaemia defined as serum calcium < 7.8 mg/dl, hypervitaminosis defined as serum
25-hydroxyvitamin D > 55 ng/ml);
Bone biomarkers (serum osteocalcin, urine cross-linked N-telopeptides of type 1 col-
lagen, urine free deoxypyridinoline; 0, 3, 12, 24 months; also 2, 14 days after first
pamidronate infusion in intervention group);
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Aris 2000 (Continued)
Serum calcium, vitamin D (25-hydroxyvitamin D, 1,25-dihydroxyvitamin D) and PTH
levels (0, 3, 12, 24 months);
Withdrawals;
Survival.
Notes 44 people with CF were eligible during the course of this study, 7 died immediately
post-operatively and were therefore not eligible for this trial. As outlined above, 3 people
died during the course of the study before the first primary end point measurement. 34
people were included in the final analyses
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear “Blocks of four” design stated (stratified on
basis of gender and severity of osteoporo-
sis using spine z-score of -3.0), but actual
method of randomisation is not discussed
Allocation concealment? Unclear Not discussed.
Blinding?
All outcomes
No Person(s) responsible for participants care
and participants were not blinded. Of out-
come assessors, only the radiologist who in-
terpreted the DXA scans was blinded
Incomplete outcome data addressed?
All outcomes
Unclear It was described that 3 participants died
during the course of the study before
the first primary end point measurement.
These participants were excluded from the
final analysis of baseline characteristics and
outcomedata.However, it was not reported
which treatment group they were in
Free of selective reporting? No Serum and urine biochemical measure-
ments that were measured at 2 days (only
after first pamidronate infusion in interven-
tion group) were not reported
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Aris 2004
Methods Randomised controlled trial; parallel design; double-blind placebo-controlled; trial du-
ration 1 year for primary outcome measure (trial was intended to be 2 years duration)
Generation of allocation sequence was stated (“blocks of four” design). Allocation con-
cealment was unclear
Withdrawals - before 6-month DXA
5 participants in total, but not stated from which group, so 48 participants were evalu-
able. Reasons for dropping out:pregnancy (n=1); diarrhoea and weight loss (n=3); dys-
phagia (n=1). The three participants with diarrhoea reported abdominal cramping, loss
of appetite, and diarrhoea before the medications began that worsened during the study
but persisted after the study medications were discontinued, one participant was on al-
endronate and two on placebo
Withdrawals - between 6 and 12 months
Intervention group: 4 drop-outs; reasons were: transplanted = 1; moved = 2; non-com-
pliance = 1.
Placebo group: 4 drop-outs; reasons were: transplanted = 2; died = 1; moved = 1
Withdrawals between 1 and 2 years
Intervention group: 9 drop-outs; reasons were: moved = 2; committed to only 1 year =
7.
Placebo group: 7 drop-outs; reasons were: moved = 1; committed to only one year = 6
Participants Single centre, adult CF centre, USA.
Inclusion criteria: CF, ambulatory, DXA showed a spine or femur T-score of -1 or less;
Exclusion criteria: primary graft failure or other post-operative morbidities that pre-
cluded long-term survival, renal insufficiency (serum creatinine > 3.0 mg/dl), active up-
per gastrointestinal disease, chronic oral glucocorticoid usage (>10 mg every day), organ
transplantation, renal insufficiency (serum creatinine > 3.0mg/dl), a history of bisphos-
phonate intolerance or use, and pregnancy
101 participants consented to be screened, 86 qualified and 53 started protocol and were
randomised
N = 48 (24 in treatment group); 23 female (9 in treatment group).
Treatment group: mean (SD) age 28 years (7 years); control group: mean (SD) age 27
years (9 years)
At baseline, osteoporosis was found in 3 participants and osteopenia was present in 20
participants in both the treatment and control group
Interventions Oral alendronate (10mg daily);
All participants received oral vitamin D (800IU/day) and oral calcium carbonate
(1000mg/day)
Outcomes Primary outcome:
BMD (spine; 0, 6, 12, 18, 24 months; DXA Hologic QDR 1000/W Waltham MA);
with 12 months data as primary outcome
Secondary outcomes:
BMD (femur; 0, 6, 12, 18, 24 months; DXA Hologic QDR 1000/W Waltham MA);
New fractures (number of fractures during study; long bone using clinical data, rib using
posteroanterior chest radiographs, vertebral using lateral chest radiographs);
Adverse events (number during study; fever, bone pain);
Serum (parathyroid hormone, 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, osteo-
calcin, bone-specific ALP) and urine (cross-linked N-telopeptides and deoxypyridino-
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Aris 2004 (Continued)
line) biochemical measurements;
Withdrawals;
Survival.
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear “Blocks of four” design stated, but actual
method of randomisation is not discussed
Allocation concealment? Unclear Not discussed.
Blinding?
All outcomes
Unclear Described as “double-blind”.
Clinicians or persons delivering treatment:
unclear if clinicians involved in the study
and clinicians managing the medical prob-
lems of the participants were all blinded
Participants: blinded.
Outcome assessors: stated that the mus-
culoskeletal radiologist who analysed base-
line and end-of-study chest radiographs
for fracture were blinded, not specifically
stated that other outcome assessors were
blinded
Incomplete outcome data addressed?
All outcomes
Unclear Described that protocol was originally de-
signed to be 2 years in length, but few par-
ticipants were willing to consent to such
a lengthy study, so protocol was revised
to measure the primary endpoint at 12
months
5 withdrawals between commencement of
protocol and 6-month outcome measures
were described, but not delineated whether
they were in treatment or control group
4 withdrawals from each group (between 6
months and 12months outcomemeasures)
were described
The primary end-point measure was anal-
ysed in 40/53 (75%) participants, hence
there is a risk of attrition bias
Stated that an intention-to-treat principle
was used in the analyses of the treatment
endpoints
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Aris 2004 (Continued)
Free of selective reporting? Yes Outcome measures that were described in
the methods section were reported in the
results section
Boyle 2005
Methods Randomised, double-blinded, placebo-controlled trial; parallel design. Trial duration 6
months (originally intended for 12 months).
Generation of allocation sequence and allocation concealment were unclear
Participants N = 40 planned for enrolment but only 5 enrolled (3 in treatment group) before study
stopped by Data and Safety Monitoring Board (see notes)
Inclusion criteria: CF; osteopenia of the lumbar spine (T-scores -1.0 to -2.5); serum 25-
hydroxyvitamin D levels ≥ 20ng/ml prior to infusion.
Exclusion criteria: existing osteoporosis, prior treatment with bisphosphonates or previ-
ous lung transplant
Interventions Intravenous zoledronate, 5mg infusion administered on a single occasionover 20minutes
All participants received supplemental oral vitamin D (800 IU) and oral calcium
(1000mg) daily
Outcomes BMD (lumbar spine) - 0, 6 months (originally planned additionally for 12 month)
Change from baseline in serum C-telopeptides at 3, 6 months (originally planned addi-
tionally for 9 and 12 months)
Notes The study was stopped by its Data and Safety Monitoring Board after 3 participants
experienced dramatic musculoskeletal pain, 2 requiring emergency room assessment.
Symptoms began 6 to 8 hours after infusion, peaked at 12 to 18 hours, and were charac-
terized by severe chest and back pain. Along with musculoskeletal pain, one participant
also experienced a fever of 104oF lasting for several hours and a rise in Tumour Necrosis
Factor-α. Although the most severe symptoms resolved within 48 to 72 hours, partici-
pants reported continued arthralgias for up to a week
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Not reported.
Allocation concealment? Unclear Not discussed.
Blinding?
All outcomes
Unclear Described as ’double-blind’.
Participants: blinded.
Not discussed if clinicians or persons deliv-
ering treatment and outcome assessors were
both blinded
22Bisphosphonates for osteoporosis in people with cystic fibrosis (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Boyle 2005 (Continued)
Incomplete outcome data addressed?
All outcomes
Yes Based on interpretation of data, we have
presumed that the 3 participants who had
severe bone painwere the 3 in the treatment
group. Clarification from the author was
requested but not received
Free of selective reporting? No Abstract only but outcome measures were
described in the results
Free of other bias? Unclear Insufficient data in abstract to be clear.
Chapman 2008
Methods Randomised, double-blinded, placebo-controlled trial; parallel design. Trial duration 24
months.
Generation of allocation sequence and allocation concealment were unclear
Participants Multientre, 2 sites, CF clinics, Australia.
Inclusion criteria: CF (diagnosis previously made by sweat chloride test and an appropri-
ate CF phenotype); ≥ 18 years; bone density T-score <-1.5 in at least one of three sites
(hip (femoral neck), lumbar spine 2 to 4 (L2 to L4) and distal forearm) in the month
before study commencement
Exclusion criteria: pre-existing, symptomatic, fragility fractures; untreated hyperthy-
roidism, primary hyperparathyroidism or hypogonadism; bisphosphonate treatment in
the three months before starting the study; serum calcium concentration below the lower
limit of the laboratory normal range; serum creatinine concentration more than 1.5
times the upper limit of the laboratory normal range; serum ALT, ALP or bilirubin more
than three times the upper limit of the laboratory normal range; on the waiting list for
lung transplantation; pregnant or lactating; considered unlikely to complete the study
N=22 (10 in treatment group); 17 male (7 in treatment group), 5 females (3 in treatment
group)
Treatment group: mean (SD) age 30.1 (2.2) years; control group: mean (SD) age 28.6
(2.4) years. Age range over all: males 21 to 47 years, females 19 to 28 years
Interventions Treatment group: intravenous zoledronic acid (zoledronate) in 100mls of normal saline
infused over 15 minutes every 3 months for 21 months (eight infusions in total). For
5 out of 63 doses, 4mg zoledronate was administered, then dose reduced to 2mg for
subsequent doses (due to febrile reactions to the higher dose in several participants)
Placebo group: 100 mls normal saline as above.
All participants were prescribed calcium carbonate 600mg and vitaminD21000 IU each
twice daily at least 3 days before the first treatment infusion and continued throughout
the study. All participants were prescribed prednisolone 25 mg orally per day for 3 days
starting on the morning of the first infusion; repeated with subsequent infusions if a
reaction to the first infusion was thought likely. If there were side effects of the study
infusion that were considered to be possibly due to the infusion during the first or any
subsequent infusion, at the discretion of the investigator and participant, oral analgesia
(paracetamol) was also administered for subsequent infusions
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Chapman 2008 (Continued)
Outcomes Bone density at hip (femoral neck), lumbar spine (L2-L4) and distal forearm:- baseline,
6, 12 and 24 months
Plain x-rays of thoracic and lumbar spine: baseline and 24months (additional films taken
as indicated to confirm any suspected fractures)
Biochemical measurements (baseline and two weeks before the 6, 12, 18 and 24 months
time-points: urea; creatinine; ALP; ALT; bilirubin; calcium (corrected); calcium (ionised)
; phosphate; 25-hydroxyvitamin D; PTH; complete blood count and differential
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Not discussed.
Allocation concealment? Unclear Not discussed.
Blinding?
All outcomes
Unclear Described as ’double-blind’.
Participants: blinded.
Outcome assessors: DXA scans were per-
formed and analysed by personnel blinded
to treatment assignment
Not specifically discussed if clinicians or
persons delivering treatment andother out-
come assessors were all blinded
Incomplete outcome data addressed?
All outcomes
Unclear Withdrawals described.
In the treatment group, 2participantswith-
drew due to side-effects, 1 due to psychi-
atric illness
In the placebo group, one participant was
lost to follow-up, one participant’s BMD
decreased to withdrawal threshold, 2 par-
ticipants were poorly compliant to study
protocols and in one participant, both
of the latter two reasons were applica-
ble. However, it was unclear which spe-
cific participants had BMD measurements
available at each time-point, particularly
for forearm measures (fewer measurements
compared with lumbar spine and femoral
neck)
Free of selective reporting? Yes Outcome measures that were described in
the methods section were reported in the
results section
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Haworth 2001
Methods Randomised controlled trial; parallel design. Trial duration planned for 1 year, but was
shortened to 6 months because of adverse events
Generation of allocation sequence and allocation concealment were unclear
Not stated if participants, providers or outcome assessors (or all) were blinded
3 participants did not complete the study (1 participant in the treatment group received
a double lung transplant and 1 participant in each group died of respiratory failure)
Participants Single centre, UK.
Inclusion criteria: CF; no organ transplantation; 70% of all eligible participants in a
longitudinal BMD study recruited after one year of follow-up; no prior treatment with
bone sparing agents; BMD Z-score of < or = -2 at lumbar spine, proximal femur or distal
forearm
N = 31 (15 in treatment group); 9 female (more in treatment group but exact number
not reported)
Mean (SD) age 26.1 (5.8) years; BMI 21.1 (2.7) kg/m2 ; FEV150.9 (20.3)%of predicted
treatment. Groups similar with respect to age, initial BMD, bone biochemistry and
respiratory disease severity
3 participants (2 from treatment group) withdrew.
Interventions Intravenous pamidronate 30 mg every 3 months for 6 months (2 doses)
All participants with pancreatic insufficiency (relevant to all except one in control group)
continued long termoral vitaminD(900 IU/day); all participants in both groups received
oral calcium (1g daily)
Outcomes BMD (lumbar spine; proximal femur (total hip); 0, 6months; DXAHologic QDR 4500
Waltham MA);
BMD (distal radius, ultradistal radius; 0, 6 months; SXA);
Adverse events (bone pain);
Withdrawals (total, due to adverse events);
Survival.
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Not reported.
Allocation concealment? Unclear Not discussed.
Blinding?
All outcomes
Unclear Not reported.
Incomplete outcome data addressed?
All outcomes
Yes Withdrawals were reported; one partici-
pant in each group died of respiratory fail-
ure and one participant in the treatment
group underwent a double lung transplant
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Haworth 2001 (Continued)
Free of selective reporting? Yes Outcome measures that were described in
the methods section were reported in the
results section
Free of other bias? Unclear Given insufficient data, we are unclear of
other bias.
ALP: alkaline phosphatase
ALT: alanine aminotransferase
BMD: bone mineral density
BMI: body mass index
CF: cystic fibrosis
DXA: dual-energy x-ray absorptiometry
FEV1: forced expiratory volume in one second
PTH: parathyroid hormone
SD: standard deviation
SXA:single energy x-ray absorptiometry
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Conway 2004 This study was a prospective open design, not a randomised controlled trial
Hardin 2005 This study assessed the effect of growth hormone on total-body bone mineral content in pre-pubertal children with
CF. It did not assess the effect of bisphosphonates
CF: cystic fibrosis
Characteristics of studies awaiting assessment [ordered by study ID]
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Papaioannou 2008
Methods Randomized, placebo-controlled trial. 6 Canadian CF specialty clinics
Computer- generated randomization code (stratified according to institution) prepared by an independent random-
ization center (McMaster In-Patient Pharmacy; Hamilton, ON, Canada), and block allocation employed to ensure
equitable distribution to each treatment group. The medication treatment arm was concealed, and all participants,
central and local site coordinators,
physicians, staff, and caregivers were blinded to treatment group allocation
Participants who received at least 80% of the study drug were classified
as being adherent to the protocol. All analyses were performed as intention-to-treat and included all available data
Stopping and study withdrawal rules were monitored by external Data Safety Monitoring Committee
A medical physicist, who was blinded to the study treatment arm and study status, reviewed all DXA scans. Radio-
graphs were sent to the central methods center, and read independently by two radiologists who were
blinded to the study treatment arm. Differences between radiologists were resolved by consensus
Participants 56 adults randomised. Participants had CF confirmed by positive sweat test result or DNA acid analysis and a BMD
T score of 1.0, as determined by dual-energy radiograph absorptiometry
Participants who had undergone organ transplantation; had endoscopy-proven oesophagitis, gastritis, and ulceration;
had metabolic bone disorders; had severe renal disease; had used systemic corticosteroids (dose, 7.5 mg/d) or other
drugs known to influence bone metabolism in the previous 6 months; or had osteomalacia and other documented
contraindications were excluded from the study
Alendronate group: 27 randomised (17 male, 10 female) mean (SD) age 28.1 (7.7) years. 4 withdrew (2 non-
compliance, 1 due to adverse event, 1 withdrew consent). 23 completed study
Placebo group: 29 randomised (17 male, 12 female) mean (SD) age 30.9 (9.7) years. 5 withdrew (2 non-compliance,
2 due to adverse event, 1 lost to follow-up). 24 completed study
Interventions Placebo or oral alendronate, 70 mg once weekly for 12 months
Medication was taken while sitting upright and with water only on an empty stomach at least 30 min before first
food or beverage of the day. In addition,
all participants received 800 IU of vitamin D and 1000 mg of calcium (500 mg supplementation, 500 mg from diet)
daily
Outcomes Compliance was measured through pill counts at each visit and patient self-report during telephone contact
In-clinic assessments at 6 and 12 months, and telephone follow-up was conducted by study staff at months 3 and 9
Clinic assessments at baseline and 12 months included a physical examination, vital signs, biochemistry (serum and
urine) tests, pulmonary
function tests (including FEV1 and FVC), the Medical Outcomes
Study 36-item short form, radiographs of the thoracic and lumbar spine, and DXA
Adverse events and drug reactions reported spontaneously and responses elicited at each contact. Safety analyses
included all vertebral fractures, osteoporosis-related fractures, adverse reactions, and abnormal findings that
had been detected through laboratory tests and physical examinations.
Documentation for all adverse events were blinded and adjudicated by the external Data Safety Monitoring Com-
mittee. All adverse events were reported regardless of attribution to study medication
Notes
BMD: bone mineral density
CF: cystic fibrosis
DXA: dual-energy radiograph absorptiometry
FEV1: forced expiratory volume at one second
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FVC: forced vital capacity
SD: standard deviation
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D A T A A N D A N A L Y S E S
Comparison 1. Bisphosphonates versus control (without lung transplantation)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Vertebral fractures 2 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 12 months 2 60 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
1.2 24 months 1 20 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
2 Non-vertebral fractures 2 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 12 months 2 60 Odds Ratio (M-H, Fixed, 95% CI) 2.11 [0.18, 25.35]
2.2 24 months 1 20 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
3 Total Fractures 2 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 12 months 2 60 Odds Ratio (M-H, Fixed, 95% CI) 2.11 [0.18, 25.35]
3.2 24 months 1 20 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
4 Percent change in BMD, lumbar
spine, DXA (Time-points)
4 Mean Difference (IV, Fixed, 95% CI) Subtotals only
4.1 6 months 4 101 Mean Difference (IV, Fixed, 95% CI) 4.61 [3.90, 5.32]
4.2 12 months 2 59 Mean Difference (IV, Fixed, 95% CI) 6.38 [5.21, 7.54]
4.3 24 months 1 19 Mean Difference (IV, Fixed, 95% CI) 5.70 [4.55, 6.85]
5 Percent change in BMD, lumbar
spine, DXA (End of study)
4 Mean Difference (IV, Fixed, 95% CI) Subtotals only
5.1 End of study 4 92 Mean Difference (IV, Fixed, 95% CI) 5.90 [4.94, 6.87]
6 Percent change in BMD,
total hip / femur, DXA
(Time-points)
3 Mean Difference (IV, Random, 95% CI) Subtotals only
6.1 6 months 3 96 Mean Difference (IV, Random, 95% CI) 3.35 [1.63, 5.07]
6.2 12 months 2 59 Mean Difference (IV, Random, 95% CI) 4.84 [2.73, 6.96]
6.3 24 months 1 19 Mean Difference (IV, Random, 95% CI) 6.73 [5.51, 7.95]
7 Percent change in BMD, total
hip/femur, DXA (End of study)
3 Mean Difference (IV, Random, 95% CI) Subtotals only
7.1 End of study 3 87 Mean Difference (IV, Random, 95% CI) 4.58 [1.92, 7.24]
8 Percent change in BMD, distal
radius, SXA (Time-points)
2 Mean Difference (IV, Random, 95% CI) Subtotals only
8.1 6 months 2 48 Mean Difference (IV, Random, 95% CI) -0.49 [-2.42, 1.45]
8.2 12 months 1 18 Mean Difference (IV, Random, 95% CI) 0.32 [-0.30, 0.94]
8.3 24 months 1 14 Mean Difference (IV, Random, 95% CI) 1.5 [0.41, 2.59]
9 Percent change in BMD, distal
radius, SXA (End of study)
2 Mean Difference (IV, Random, 95% CI) Subtotals only
9.1 End of study 2 42 Mean Difference (IV, Random, 95% CI) 0.01 [-3.12, 3.14]
10 Percent change in BMD,
ultradistal radius, SXA
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
10.1 6 months 1 Mean Difference (IV, Fixed, 95% CI) Not estimable
11 Bone pain 4 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
11.1 Oral bisphosphonates 1 48 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
11.2 Intravenous
bisphosphonates
3 60 Odds Ratio (M-H, Fixed, 95% CI) 14.17 [3.64, 55.17]
11.3 All routes of
bisphosphonate administration
4 108 Odds Ratio (M-H, Fixed, 95% CI) 14.17 [3.64, 55.17]
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12 Fever 4 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
12.1 Oral bisphosphonates 1 48 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
12.2 Intravenous
bisphosphonates
3 55 Odds Ratio (M-H, Fixed, 95% CI) 12.64 [2.31, 69.11]
12.3 All routes of
bisphosphonate administration
4 103 Odds Ratio (M-H, Fixed, 95% CI) 12.64 [2.31, 69.11]
13 Withdrawals, due to adverse
events
3 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
13.1 6 months 2 53 Odds Ratio (M-H, Fixed, 95% CI) 3.95 [0.14, 108.09]
13.2 12 months 2 70 Odds Ratio (M-H, Fixed, 95% CI) 7.35 [0.31, 173.13]
13.3 24 months 1 22 Odds Ratio (M-H, Fixed, 95% CI) 7.35 [0.31, 173.13]
14 Withdrawals, total 3 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
14.1 6 months 2 53 Odds Ratio (M-H, Fixed, 95% CI) 2.83 [0.39, 20.73]
14.2 12 months 2 70 Odds Ratio (M-H, Fixed, 95% CI) 1.08 [0.31, 3.73]
14.3 24 months 1 22 Odds Ratio (M-H, Fixed, 95% CI) 0.43 [0.07, 2.50]
15 Survival 4 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
15.1 6 months 2 36 Odds Ratio (M-H, Fixed, 95% CI) 0.93 [0.05, 16.39]
15.2 12 months 1 48 Odds Ratio (M-H, Fixed, 95% CI) 3.13 [0.12, 80.68]
15.3 24 months 1 22 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
Comparison 2. Bisphosphonates versus control (with lung transplantation)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Vertebral fractures 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 24 months 1 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
2 Non-vertebral fractures 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
2.1 24 months 1 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
3 Total Fractures 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
3.1 24 months 1 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
4 Percent change in BMD, lumbar
spine, DXA
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
4.1 24 months 1 Mean Difference (IV, Fixed, 95% CI) Not estimable
5 Percent change in BMD, femur,
DXA
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
5.1 24 months 1 Mean Difference (IV, Fixed, 95% CI) Not estimable
6 Bone pain 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
6.1 24 months 1 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
7 Withdrawals, due to adverse
events
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
8 Withdrawals, total 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
8.1 24 months 1 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
9 Survival 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
9.1 24 months 1 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
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Analysis 1.1. Comparison 1 Bisphosphonates versus control (without lung transplantation), Outcome 1
Vertebral fractures.
Review: Bisphosphonates for osteoporosis in people with cystic fibrosis
Comparison: 1 Bisphosphonates versus control (without lung transplantation)
Outcome: 1 Vertebral fractures
Study or subgroup Bisphosphonate Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 12 months
Aris 2004 0/20 0/20 Not estimable
Chapman 2009 0/10 0/10 Not estimable
Papaioannou 2008 0/23 2/24 100.0 % 0.19 [ 0.01, 4.21 ]
Subtotal (95% CI) 53 54 100.0 % 0.19 [ 0.01, 4.21 ]
Total events: 0 (Bisphosphonate), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.05 (P = 0.29)
2 24 months
Chapman 2009 0/10 0/10 Not estimable
Haworth 2010 0/12 0/12 Not estimable
Subtotal (95% CI) 22 22 Not estimable
Total events: 0 (Bisphosphonate), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
0.005 0.1 1 10 200
Favours bisphosphonates Favours control
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Analysis 1.2. Comparison 1 Bisphosphonates versus control (without lung transplantation), Outcome 2
Non-vertebral fractures.
Review: Bisphosphonates for osteoporosis in people with cystic fibrosis
Comparison: 1 Bisphosphonates versus control (without lung transplantation)
Outcome: 2 Non-vertebral fractures
Study or subgroup Bisphosphonate Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 12 months
Aris 2004 2/20 1/20 100.0 % 2.11 [ 0.18, 25.35 ]
Chapman 2009 0/10 0/10 Not estimable
Subtotal (95% CI) 30 30 100.0 % 2.11 [ 0.18, 25.35 ]
Total events: 2 (Bisphosphonate), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.59 (P = 0.56)
2 24 months
Chapman 2009 0/10 0/10 Not estimable
Haworth 2010 0/12 0/12 Not estimable
Subtotal (95% CI) 22 22 Not estimable
Total events: 0 (Bisphosphonate), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
0.01 0.1 1 10 100
Favours bisphosphonates Favours control
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Analysis 1.3. Comparison 1 Bisphosphonates versus control (without lung transplantation), Outcome 3
Total Fractures.
Review: Bisphosphonates for osteoporosis in people with cystic fibrosis
Comparison: 1 Bisphosphonates versus control (without lung transplantation)
Outcome: 3 Total Fractures
Study or subgroup Bisphosphonate Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 12 months
Aris 2004 2/20 1/20 27.3 % 2.11 [ 0.18, 25.35 ]
Chapman 2009 0/10 0/10 Not estimable
Papaioannou 2008 0/23 2/24 72.7 % 0.19 [ 0.01, 4.21 ]
Subtotal (95% CI) 53 54 100.0 % 0.72 [ 0.13, 3.80 ]
Total events: 2 (Bisphosphonate), 3 (Control)
Heterogeneity: Chi2 = 1.43, df = 1 (P = 0.23); I2 =30%
Test for overall effect: Z = 0.39 (P = 0.69)
2 24 months
Chapman 2009 0/10 0/10 Not estimable
Haworth 2010 0/12 0/12 Not estimable
Subtotal (95% CI) 22 22 Not estimable
Total events: 0 (Bisphosphonate), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
0.01 0.1 1 10 100
Favours biphosphonates Favours control
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Analysis 1.4. Comparison 1 Bisphosphonates versus control (without lung transplantation), Outcome 4
Percent change in BMD, lumbar spine, DXA (Time-points).
Review: Bisphosphonates for osteoporosis in people with cystic fibrosis
Comparison: 1 Bisphosphonates versus control (without lung transplantation)
Outcome: 4 Per cent change in BMD, lumbar spine, DXA (Time-points)
Study or subgroup Bisphosphonate Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 6 months
Aris 2004 24 4.5 (2.45) 24 -1 (2.45) 26.1 % 5.50 [ 4.11, 6.89 ]
Boyle 2005 3 4.7 (0.6) 2 0 (0) Not estimable
Chapman 2009 8 5.35 (0.76) 12 1.19 (1.2) 67.9 % 4.16 [ 3.30, 5.02 ]
Haworth 2001 13 4.1 (3.4) 15 -1.7 (4.4) 6.0 % 5.80 [ 2.91, 8.69 ]
Subtotal (95% CI) 48 53 100.0 % 4.61 [ 3.90, 5.32 ]
Heterogeneity: Chi2 = 3.29, df = 2 (P = 0.19); I2 =39%
Test for overall effect: Z = 12.75 (P < 0.00001)
2 12 months
Aris 2004 20 4.9 (3) 20 -1.8 (4) 20.9 % 6.70 [ 4.51, 8.89 ]
Chapman 2009 9 6.6 (1.5) 10 0.35 (1.55) 53.2 % 6.25 [ 4.88, 7.62 ]
Haworth 2010 14 4.3 (7) 15 -1.2 (6.4) 4.2 % 5.50 [ 0.61, 10.39 ]
Papaioannou 2008 23 5.2 (3.67) 25 -0.08 (3.93) 21.7 % 5.28 [ 3.13, 7.43 ]
Subtotal (95% CI) 66 70 100.0 % 6.10 [ 5.10, 7.10 ]
Heterogeneity: Chi2 = 0.95, df = 3 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 11.94 (P < 0.00001)
3 24 months
Chapman 2009 10 6.14 (1.86) 9 0.44 (0.1) 92.1 % 5.70 [ 4.55, 6.85 ]
Haworth 2010 12 3.1 (5.5) 12 0.1 (4.3) 7.9 % 3.00 [ -0.95, 6.95 ]
Subtotal (95% CI) 22 21 100.0 % 5.49 [ 4.38, 6.60 ]
Heterogeneity: Chi2 = 1.65, df = 1 (P = 0.20); I2 =40%
Test for overall effect: Z = 9.70 (P < 0.00001)
Test for subgroup differences: Chi2 = 6.06, df = 2 (P = 0.05), I2 =67%
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Analysis 1.5. Comparison 1 Bisphosphonates versus control (without lung transplantation), Outcome 5
Percent change in BMD, lumbar spine, DXA (End of study).
Review: Bisphosphonates for osteoporosis in people with cystic fibrosis
Comparison: 1 Bisphosphonates versus control (without lung transplantation)
Outcome: 5 Per cent change in BMD, lumbar spine, DXA (End of study)
Study or subgroup Bisphosphonate Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 End of study
Aris 2004 20 4.9 (3) 20 -1.8 (4) 15.3 % 6.70 [ 4.51, 8.89 ]
Boyle 2005 3 4.7 (0.6) 2 0 (0) Not estimable
Chapman 2009 10 6.14 (1.86) 9 0.44 (0.1) 55.2 % 5.70 [ 4.55, 6.85 ]
Haworth 2001 13 4.1 (3.4) 15 -1.7 (4.4) 8.8 % 5.80 [ 2.91, 8.69 ]
Haworth 2010 12 3.1 (5.5) 12 0.1 (4.3) 4.7 % 3.00 [ -0.95, 6.95 ]
Papaioannou 2008 23 5.2 (3.67) 25 -0.08 (3.93) 15.9 % 5.28 [ 3.13, 7.43 ]
Subtotal (95% CI) 81 83 100.0 % 5.67 [ 4.81, 6.53 ]
Heterogeneity: Chi2 = 2.74, df = 4 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 12.95 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.6. Comparison 1 Bisphosphonates versus control (without lung transplantation), Outcome 6
Percent change in BMD, total hip / femur, DXA (Time-points).
Review: Bisphosphonates for osteoporosis in people with cystic fibrosis
Comparison: 1 Bisphosphonates versus control (without lung transplantation)
Outcome: 6 Per cent change in BMD, total hip / femur, DXA (Time-points)
Study or subgroup Bisphosphonate Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 6 months
Aris 2004 24 2.2 (2.45) 24 0 (2.45) 36.2 % 2.20 [ 0.81, 3.59 ]
Chapman 2009 8 3.2 (1.6) 12 -1.43 (0.43) 39.2 % 4.63 [ 3.49, 5.77 ]
Haworth 2001 13 1.7 (2.5) 15 -1.3 (3.9) 24.6 % 3.00 [ 0.60, 5.40 ]
Subtotal (95% CI) 45 51 100.0 % 3.35 [ 1.63, 5.07 ]
Heterogeneity: Tau2 = 1.62; Chi2 = 7.32, df = 2 (P = 0.03); I2 =73%
Test for overall effect: Z = 3.83 (P = 0.00013)
2 12 months
Aris 2004 20 2.8 (3.2) 20 -0.7 (4.7) 20.6 % 3.50 [ 1.01, 5.99 ]
Chapman 2009 9 4.12 (1.8) 10 -1.59 (1.4) 38.0 % 5.71 [ 4.25, 7.17 ]
Haworth 2010 13 2.1 (7.3) 15 -1.7 (2.9) 8.9 % 3.80 [ -0.43, 8.03 ]
Papaioannou 2008 23 2.14 (3.32) 25 -1.3 (2.7) 32.5 % 3.44 [ 1.72, 5.16 ]
Subtotal (95% CI) 65 70 100.0 % 4.35 [ 2.99, 5.70 ]
Heterogeneity: Tau2 = 0.71; Chi2 = 4.81, df = 3 (P = 0.19); I2 =38%
Test for overall effect: Z = 6.28 (P < 0.00001)
3 24 months
Chapman 2009 10 4.23 (1.3) 9 -2.5 (1.41) 75.1 % 6.73 [ 5.51, 7.95 ]
Haworth 2010 11 2 (5.8) 12 -2 (3.6) 24.9 % 4.00 [ 0.01, 7.99 ]
Subtotal (95% CI) 21 21 100.0 % 6.05 [ 3.74, 8.36 ]
Heterogeneity: Tau2 = 1.46; Chi2 = 1.65, df = 1 (P = 0.20); I2 =39%
Test for overall effect: Z = 5.13 (P < 0.00001)
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Analysis 1.7. Comparison 1 Bisphosphonates versus control (without lung transplantation), Outcome 7
Percent change in BMD, total hip/femur, DXA (End of study).
Review: Bisphosphonates for osteoporosis in people with cystic fibrosis
Comparison: 1 Bisphosphonates versus control (without lung transplantation)
Outcome: 7 Per cent change in BMD, total hip/femur, DXA (End of study)
Study or subgroup Bisphosphonate Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of study
Aris 2004 20 2.8 (3.2) 20 -0.7 (4.7) 19.0 % 3.50 [ 1.01, 5.99 ]
Chapman 2009 10 4.23 (1.3) 9 -2.5 (1.41) 25.9 % 6.73 [ 5.51, 7.95 ]
Haworth 2001 13 1.7 (2.5) 15 -1.3 (3.9) 19.5 % 3.00 [ 0.60, 5.40 ]
Haworth 2010 11 2 (5.8) 12 -2 (3.6) 12.3 % 4.00 [ 0.01, 7.99 ]
Papaioannou 2008 23 2.14 (3.32) 25 -1.3 (2.7) 23.3 % 3.44 [ 1.72, 5.16 ]
Subtotal (95% CI) 77 81 100.0 % 4.29 [ 2.45, 6.13 ]
Heterogeneity: Tau2 = 3.02; Chi2 = 15.14, df = 4 (P = 0.004); I2 =74%
Test for overall effect: Z = 4.57 (P < 0.00001)
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Analysis 1.8. Comparison 1 Bisphosphonates versus control (without lung transplantation), Outcome 8
Percent change in BMD, distal radius, SXA (Time-points).
Review: Bisphosphonates for osteoporosis in people with cystic fibrosis
Comparison: 1 Bisphosphonates versus control (without lung transplantation)
Outcome: 8 Per cent change in BMD, distal radius, SXA (Time-points)
Study or subgroup Bisphosphonate Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 6 months
Chapman 2009 8 0.55 (0.93) 12 0.23 (0.89) 60.1 % 0.32 [ -0.50, 1.14 ]
Haworth 2001 13 -1.1 (2.9) 15 0.6 (2.3) 39.9 % -1.70 [ -3.66, 0.26 ]
Subtotal (95% CI) 21 27 100.0 % -0.49 [ -2.42, 1.45 ]
Heterogeneity: Tau2 = 1.45; Chi2 = 3.48, df = 1 (P = 0.06); I2 =71%
Test for overall effect: Z = 0.49 (P = 0.62)
2 12 months
Chapman 2009 9 0.93 (0.64) 9 0.61 (0.71) 100.0 % 0.32 [ -0.30, 0.94 ]
Subtotal (95% CI) 9 9 100.0 % 0.32 [ -0.30, 0.94 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.00 (P = 0.32)
3 24 months
Chapman 2009 7 0.39 (1.17) 7 -1.11 (0.89) 100.0 % 1.50 [ 0.41, 2.59 ]
Subtotal (95% CI) 7 7 100.0 % 1.50 [ 0.41, 2.59 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.70 (P = 0.0069)
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Analysis 1.9. Comparison 1 Bisphosphonates versus control (without lung transplantation), Outcome 9
Percent change in BMD, distal radius, SXA (End of study).
Review: Bisphosphonates for osteoporosis in people with cystic fibrosis
Comparison: 1 Bisphosphonates versus control (without lung transplantation)
Outcome: 9 Per cent change in BMD, distal radius, SXA (End of study)
Study or subgroup Bisphosphonate Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of study
Chapman 2009 7 0.39 (1.17) 7 -1.11 (0.89) 53.4 % 1.50 [ 0.41, 2.59 ]
Haworth 2001 13 -1.1 (2.9) 15 0.6 (2.3) 46.6 % -1.70 [ -3.66, 0.26 ]
Subtotal (95% CI) 20 22 100.0 % 0.01 [ -3.12, 3.14 ]
Heterogeneity: Tau2 = 4.47; Chi2 = 7.83, df = 1 (P = 0.01); I2 =87%
Test for overall effect: Z = 0.00 (P = 1.0)
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Analysis 1.10. Comparison 1 Bisphosphonates versus control (without lung transplantation), Outcome 10
Percent change in BMD, ultradistal radius, SXA.
Review: Bisphosphonates for osteoporosis in people with cystic fibrosis
Comparison: 1 Bisphosphonates versus control (without lung transplantation)
Outcome: 10 Per cent change in BMD, ultra distal radius, SXA
Study or subgroup Bisphosphonate Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 6 months
Haworth 2001 13 -2.2 (3.5) 15 0.5 (4.3) -2.70 [ -5.59, 0.19 ]
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Analysis 1.11. Comparison 1 Bisphosphonates versus control (without lung transplantation), Outcome 11
Bone pain.
Review: Bisphosphonates for osteoporosis in people with cystic fibrosis
Comparison: 1 Bisphosphonates versus control (without lung transplantation)
Outcome: 11 Quality of Life
Study or subgroup Bisphosphonate Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Physical component
Papaioannou 2008 23 -1.18 (4.93) 24 -3.69 (8.33) 68.9 % 2.51 [ -1.38, 6.40 ]
Subtotal (95% CI) 23 24 68.9 % 2.51 [ -1.38, 6.40 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.26 (P = 0.21)
2 Mental component
Papaioannou 2008 23 -2.67 (7.55) 24 3.26 (12.27) 31.1 % -5.93 [ -11.73, -0.13 ]
Subtotal (95% CI) 23 24 31.1 % -5.93 [ -11.73, -0.13 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.00 (P = 0.045)
Total (95% CI) 46 48 100.0 % -0.11 [ -3.35, 3.12 ]
Heterogeneity: Chi2 = 5.61, df = 1 (P = 0.02); I2 =82%
Test for overall effect: Z = 0.07 (P = 0.94)
Test for subgroup differences: Chi2 = 5.61, df = 1 (P = 0.02), I2 =82%
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Analysis 1.12. Comparison 1 Bisphosphonates versus control (without lung transplantation), Outcome 12
Fever.
Review: Bisphosphonates for osteoporosis in people with cystic fibrosis
Comparison: 1 Bisphosphonates versus control (without lung transplantation)
Outcome: 12 Bone pain
Study or subgroup Bisphosphonate Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Oral bisphosphonates
Aris 2004 0/24 0/24 Not estimable
Haworth 2010 9/17 0/19 100.0 % 43.59 [ 2.27, 837.56 ]
Papaioannou 2008 0/23 0/24 Not estimable
Subtotal (95% CI) 64 67 100.0 % 43.59 [ 2.27, 837.56 ]
Total events: 9 (Bisphosphonate), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.50 (P = 0.012)
2 Intravenous bisphosphonates
Boyle 2005 3/3 0/2 5.5 % 35.00 [ 0.50, 2435.69 ]
Chapman 2009 4/10 2/12 84.5 % 3.33 [ 0.46, 24.05 ]
Haworth 2001 11/15 0/18 10.0 % 94.56 [ 4.65, 1924.08 ]
Subtotal (95% CI) 28 32 100.0 % 14.17 [ 3.64, 55.17 ]
Total events: 18 (Bisphosphonate), 2 (Control)
Heterogeneity: Chi2 = 3.76, df = 2 (P = 0.15); I2 =47%
Test for overall effect: Z = 3.82 (P = 0.00013)
3 All routes of bisphosphonate administration
Aris 2004 0/24 0/24 Not estimable
Boyle 2005 3/3 0/2 4.7 % 35.00 [ 0.50, 2435.69 ]
Chapman 2009 4/10 2/12 72.0 % 3.33 [ 0.46, 24.05 ]
Haworth 2001 11/15 0/18 8.5 % 94.56 [ 4.65, 1924.08 ]
Haworth 2010 9/17 0/19 14.8 % 43.59 [ 2.27, 837.56 ]
Papaioannou 2008 0/23 0/24 Not estimable
Subtotal (95% CI) 92 99 100.0 % 18.52 [ 5.39, 63.57 ]
Total events: 27 (Bisphosphonate), 2 (Control)
Heterogeneity: Chi2 = 4.43, df = 3 (P = 0.22); I2 =32%
Test for overall effect: Z = 4.64 (P < 0.00001)
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Analysis 1.13. Comparison 1 Bisphosphonates versus control (without lung transplantation), Outcome 13
Withdrawals, due to adverse events.
Review: Bisphosphonates for osteoporosis in people with cystic fibrosis
Comparison: 1 Bisphosphonates versus control (without lung transplantation)
Outcome: 13 Fever
Study or subgroup Bisphosphonate Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Oral bisphosphonates
Aris 2004 0/24 0/24 Not estimable
Subtotal (95% CI) 24 24 Not estimable
Total events: 0 (Bisphosphonate), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Intravenous bisphosphonates
Boyle 2005 1/3 0/2 38.7 % 3.00 [ 0.08, 115.34 ]
Chapman 2009 8/10 1/12 19.7 % 44.00 [ 3.38, 573.41 ]
Haworth 2001 2/13 0/15 41.6 % 6.74 [ 0.29, 154.26 ]
Subtotal (95% CI) 26 29 100.0 % 12.64 [ 2.31, 69.11 ]
Total events: 11 (Bisphosphonate), 1 (Control)
Heterogeneity: Chi2 = 1.66, df = 2 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 2.93 (P = 0.0034)
3 All routes of bisphosphonate administration
Aris 2004 0/24 0/24 Not estimable
Boyle 2005 1/3 0/2 38.7 % 3.00 [ 0.08, 115.34 ]
Chapman 2009 8/10 1/12 19.7 % 44.00 [ 3.38, 573.41 ]
Haworth 2001 2/13 0/15 41.6 % 6.74 [ 0.29, 154.26 ]
Subtotal (95% CI) 50 53 100.0 % 12.64 [ 2.31, 69.11 ]
Total events: 11 (Bisphosphonate), 1 (Control)
Heterogeneity: Chi2 = 1.66, df = 2 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 2.93 (P = 0.0034)
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Analysis 1.14. Comparison 1 Bisphosphonates versus control (without lung transplantation), Outcome 14
Withdrawals, total.
Review: Bisphosphonates for osteoporosis in people with cystic fibrosis
Comparison: 1 Bisphosphonates versus control (without lung transplantation)
Outcome: 14 Withdrawals, due to adverse events
Study or subgroup Bisphosphonate Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 6 months
Chapman 2009 1/10 0/12 100.0 % 3.95 [ 0.14, 108.09 ]
Haworth 2001 0/15 0/16 Not estimable
Subtotal (95% CI) 25 28 100.0 % 3.95 [ 0.14, 108.09 ]
Total events: 1 (Bisphosphonate), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.81 (P = 0.42)
2 12 months
Aris 2004 0/24 0/24 Not estimable
Chapman 2009 2/10 0/12 14.1 % 7.35 [ 0.31, 173.13 ]
Haworth 2010 6/17 0/19 12.0 % 22.04 [ 1.13, 428.52 ]
Papaioannou 2008 1/27 2/29 73.9 % 0.52 [ 0.04, 6.08 ]
Subtotal (95% CI) 78 84 100.0 % 4.07 [ 1.11, 14.90 ]
Total events: 9 (Bisphosphonate), 2 (Control)
Heterogeneity: Chi2 = 4.07, df = 2 (P = 0.13); I2 =51%
Test for overall effect: Z = 2.12 (P = 0.034)
3 24 months
Chapman 2009 2/10 0/12 56.2 % 7.35 [ 0.31, 173.13 ]
Haworth 2010 7/17 0/19 43.8 % 27.86 [ 1.44, 537.26 ]
Subtotal (95% CI) 27 31 100.0 % 16.34 [ 1.98, 134.89 ]
Total events: 9 (Bisphosphonate), 0 (Control)
Heterogeneity: Chi2 = 0.37, df = 1 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 2.59 (P = 0.0095)
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Analysis 1.15. Comparison 1 Bisphosphonates versus control (without lung transplantation), Outcome 15
Survival.
Review: Bisphosphonates for osteoporosis in people with cystic fibrosis
Comparison: 1 Bisphosphonates versus control (without lung transplantation)
Outcome: 15 Withdrawals, total
Study or subgroup Bisphosphonate Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 6 months
Chapman 2009 1/10 0/12 32.1 % 3.95 [ 0.14, 108.09 ]
Haworth 2001 2/15 1/16 67.9 % 2.31 [ 0.19, 28.47 ]
Subtotal (95% CI) 25 28 100.0 % 2.83 [ 0.39, 20.73 ]
Total events: 3 (Bisphosphonate), 1 (Control)
Heterogeneity: Chi2 = 0.06, df = 1 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 1.03 (P = 0.31)
2 12 months
Aris 2004 4/24 4/24 37.5 % 1.00 [ 0.22, 4.56 ]
Chapman 2009 2/10 2/12 16.4 % 1.25 [ 0.14, 10.94 ]
Papaioannou 2008 4/27 5/29 46.2 % 0.83 [ 0.20, 3.50 ]
Subtotal (95% CI) 61 65 100.0 % 0.96 [ 0.38, 2.46 ]
Total events: 10 (Bisphosphonate), 11 (Control)
Heterogeneity: Chi2 = 0.10, df = 2 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 0.08 (P = 0.94)
3 24 months
Chapman 2009 3/10 6/12 52.2 % 0.43 [ 0.07, 2.50 ]
Haworth 2010 8/17 7/19 47.8 % 1.52 [ 0.40, 5.78 ]
Subtotal (95% CI) 27 31 100.0 % 0.95 [ 0.34, 2.69 ]
Total events: 11 (Bisphosphonate), 13 (Control)
Heterogeneity: Chi2 = 1.27, df = 1 (P = 0.26); I2 =21%
Test for overall effect: Z = 0.09 (P = 0.93)
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Analysis 2.1. Comparison 2 Bisphosphonates versus control (with lung transplantation), Outcome 1
Vertebral fractures.
Review: Bisphosphonates for osteoporosis in people with cystic fibrosis
Comparison: 2 Bisphosphonates versus control (with lung transplantation)
Outcome: 1 Vertebral fractures
Study or subgroup Bisphosphonate Control Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 24 months
Aris 2000 3/16 1/18 3.92 [ 0.36, 42.20 ]
0.01 0.1 1 10 100
Favours experimental Favours control
Analysis 2.2. Comparison 2 Bisphosphonates versus control (with lung transplantation), Outcome 2 Non-
vertebral fractures.
Review: Bisphosphonates for osteoporosis in people with cystic fibrosis
Comparison: 2 Bisphosphonates versus control (with lung transplantation)
Outcome: 2 Non-vertebral fractures
Study or subgroup Bisphosphonate Control Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 24 months
Aris 2000 3/16 6/18 0.46 [ 0.09, 2.27 ]
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Analysis 2.3. Comparison 2 Bisphosphonates versus control (with lung transplantation), Outcome 3 Total
Fractures.
Review: Bisphosphonates for osteoporosis in people with cystic fibrosis
Comparison: 2 Bisphosphonates versus control (with lung transplantation)
Outcome: 3 Total Fractures
Study or subgroup Bisphosphonate Control Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 24 months
Aris 2000 6/16 7/18 0.94 [ 0.24, 3.77 ]
0.01 0.1 1 10 100
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Analysis 2.4. Comparison 2 Bisphosphonates versus control (with lung transplantation), Outcome 4
Percent change in BMD, lumbar spine, DXA.
Review: Bisphosphonates for osteoporosis in people with cystic fibrosis
Comparison: 2 Bisphosphonates versus control (with lung transplantation)
Outcome: 4 Per cent change in BMD, lumbar spine, DXA
Study or subgroup Bisphosphonate Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 24 months
Aris 2000 16 8.8 (2.5) 18 2.6 (3.2) 6.20 [ 4.28, 8.12 ]
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Analysis 2.5. Comparison 2 Bisphosphonates versus control (with lung transplantation), Outcome 5
Percent change in BMD, femur, DXA.
Review: Bisphosphonates for osteoporosis in people with cystic fibrosis
Comparison: 2 Bisphosphonates versus control (with lung transplantation)
Outcome: 5 Per cent change in BMD, femur, DXA
Study or subgroup Bisphosphonate Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 24 months
Aris 2000 16 8.2 (3.8) 18 0.3 (2.2) 7.90 [ 5.78, 10.02 ]
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Analysis 2.6. Comparison 2 Bisphosphonates versus control (with lung transplantation), Outcome 6 Bone
pain.
Review: Bisphosphonates for osteoporosis in people with cystic fibrosis
Comparison: 2 Bisphosphonates versus control (with lung transplantation)
Outcome: 6 Bone pain
Study or subgroup Bisphosphonate Control Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 24 months
Aris 2000 0/16 0/18 Not estimable
0.5 0.7 1 1.5 2
Favours pamidronate Favours control
47Bisphosphonates for osteoporosis in people with cystic fibrosis (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.7. Comparison 2 Bisphosphonates versus control (with lung transplantation), Outcome 7
Withdrawals, due to adverse events.
Review: Bisphosphonates for osteoporosis in people with cystic fibrosis
Comparison: 2 Bisphosphonates versus control (with lung transplantation)
Outcome: 7 Withdrawals, due to adverse events
Study or subgroup Bisphosphonate Control Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Aris 2000 0/16 0/18 Not estimable
0.01 0.1 1 10 100
Favours treatment Favours control
Analysis 2.8. Comparison 2 Bisphosphonates versus control (with lung transplantation), Outcome 8
Withdrawals, total.
Review: Bisphosphonates for osteoporosis in people with cystic fibrosis
Comparison: 2 Bisphosphonates versus control (with lung transplantation)
Outcome: 8 Withdrawals, total
Study or subgroup Bisphosphonate Control Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 24 months
Aris 2000 0/16 0/18 Not estimable
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Analysis 2.9. Comparison 2 Bisphosphonates versus control (with lung transplantation), Outcome 9
Survival.
Review: Bisphosphonates for osteoporosis in people with cystic fibrosis
Comparison: 2 Bisphosphonates versus control (with lung transplantation)
Outcome: 9 Survival
Study or subgroup Bisphosphonate Control Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 24 months
Aris 2000 16/16 18/18 Not estimable
0.1 0.2 0.5 1 2 5 10
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A P P E N D I C E S
Appendix 1. PubMed search strategy
Search terms
zoledronate AND cystic fibrosis
Appendix 2. PubMed search strategy
Search terms
“Diphosphonates” [Mesh] AND “Cystic Fibrosis” [Mesh]
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WH A T ’ S N E W
Last assessed as up-to-date: 11 August 2009.
Date Event Description
26 April 2010 Amended Contact details updated.
H I S T O R Y
Protocol first published: Issue 2, 2000
Review first published: Issue 4, 2001
Date Event Description
18 July 2009 New citation required and conclusions have changed A new review team has updated the review. As part of
this update the sections ’Methods’ and ’Risk of Bias in
included studies’ have been substantively revised and
updated
18 July 2009 New search has been performed A search of the Group’s Cystic Fibrosis Trials Register
was run in October 2008. Five references to four new
trials were identified; two trials have been included
(Aris 2004; Chapman 2008) and two trials have been
excluded (Conway 2004; Hardin 2005).
One newly identified trial has been listed as ’Awaiting
classification’ until the authors have been able to con-
tact the trial investigators (Papaioannou 2008).
10 November 2004 New search has been performed A search of the Group’s Cystic Fibrosis Trials Register
was run in August 2004, but no new references were
identified
12 November 2003 New search has been performed The searches identified no new studies to be included
in the review. Minor style changes have been made
13 November 2002 New search has been performed An additional reference [abstract] to the Haworth
2001 trial has been incorporated into the review
20 August 2001 New citation required and conclusions have changed Substantive amendment
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